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Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and
mortality.
Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are
intended to support patients, clinicians, and other health care professionals in their decisions about the
prevention and treatment of VTE in patients with cancer.
Methods: ASH formed a multidisciplinary guideline panel balanced to minimize potential
bias from conflicts of interest. The guideline development process was supported by up-
dated or new systematic evidence reviews. The Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) approach was used to assess evidence and make
recommendations.
Results: Recommendations address mechanical and pharmacological prophylaxis in hospitalized
medical patients with cancer, those undergoing a surgical procedure, and ambulatory patients
receiving cancer chemotherapy. The recommendations also address the use of anticoagulation
for the initial, short-term, and long-term treatment of VTE in patients with cancer.
Conclusions: Strong recommendations include not using thromboprophylaxis in ambulatory patients
receiving cancer chemotherapy at low risk of VTE and to use low-molecular-weight heparin (LMWH) for
initial treatment of VTE in patients with cancer. Conditional recommendations include using
thromboprophylaxis in hospitalized medical patients with cancer, LMWH or fondaparinux for surgical
patients with cancer, LMWH or direct oral anticoagulants (DOAC) in ambulatory patients with cancer
receiving systemic therapy at high risk of VTE and LMWH or DOAC for initial treatment of VTE, DOAC
for the short-term treatment of VTE, and LMWH or DOAC for the long-term treatment of VTE in patients
with cancer.
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Summary of recommendations
These guidelines are based on updated and original systematic
reviews of evidence conducted under the direction of the
McMaster University GRADE Center with international collabo-
rators. The panel followed best practice for guideline develop-
ment recommended by the National Academy of Medicine
(formerly Institute of Medicine) and the Guidelines International
Network (GIN).1-4 The panel used the Grading of Recommen-
dations Assessment, Development, and Evaluation (GRADE)
approach to assess the certainty in the evidence and formulate
recommendations.5-11 Patients with cancer are at greater risk
for venous thromboembolism (VTE) compared with the general
population, resulting in considerable morbidity, mortality, and
costs. Although 5% to 20% of patients with cancer develop
a VTE, ;20% of all VTE cases occur in patients with cancer.
The risks of VTE, bleeding, and early mortality among patients
receiving systemic cancer therapy vary by cancer type and
treatment, as well as patient-specific factors. In addition to
the overall increased risk for VTE among patients with cancer,
VTE risk is especially high among certain cancer subgroups,
hospitalized patients, those undergoing active antineoplas-
tic therapy, and those receiving certain supportive care
measures.12,13 Cancer patients who develop VTE are at
greater risk for recurrent VTE and early death. There are few
data on the impact of thrombosis on quality of life for cancer
patients. Nevertheless, the occurrence of VTE for patients
with cancer may interfere with planned chemotherapy regi-
mens, worsen patient quality of life, increase the risk of cancer
recurrence and mortality, and result in increased costs compared
with patients without cancer who experience VTE. Pharmacologic
options for VTE treatment and prevention include unfractionated
heparin (UFH), low-molecular-weight heparins (LMWHs), fonda-
parinux (an indirect synthetic inhibitor of activated factor Xa),
vitamin K antagonists (VKAs), and direct oral anticoagulants
(DOACs; previously known as novel oral anticoagulants), in-
cluding direct thrombin inhibitors and direct factor Xa inhibitors.
Treatment or prophylaxis of VTE for patients with cancer must
always balance the risk of recurrent VTE events with the increased
risk of anticoagulant-related bleeding and take into consider-
ation the consequences of these outcomes (including mortal-
ity, financial cost, quality of life), as well as patient values and
preferences.14
Interpretation of strong and
conditional recommendations
The strength of a recommendation is expressed as strong (“the
guideline panel recommends...”) or conditional (“the guideline panel
suggests…”) and has the following interpretation:
Strong recommendation
c For patients: most individuals in this situation would want the
recommended course of action, and only a small proportion
would not.
c For clinicians: most individuals should follow the recommended
course of action. Formal decision aids are not likely to be needed
to help individual patients make decisions consistent with their
values and preferences.
c For policy makers: the recommendation can be adopted as
policy in most situations. Adherence to this recommendation
according to the guideline could be used as a quality criterion or
performance indicator.
c For researchers: the recommendation is supported by credible
research or other convincing judgments that make addi-
tional research unlikely to alter the recommendation. On
occasion, a strong recommendation is based on low or very
low certainty in the evidence. In such instances, further
research may provide important information that alters the
recommendations.
Conditional recommendation
c For patients: the majority of individuals in this situation would
want the suggested course of action, but many would not.
Decision aids may be useful in helping patients to make
decisions consistent with their individual risks, values, and
preferences.
c For clinicians: recognize that different choices will be appropri-
ate for individual patients and that you must help each patient
arrive at a management decision consistent with their values and
preferences. Decision aids may be useful in helping individuals
to make decisions consistent with their individual risks, values,
and preferences.
c For policy makers: policymaking will require substantial
debate and involvement of various stakeholders. Performance
measures about the suggested course of action should focus
on whether an appropriate decision-making process is duly
documented.
c For researchers: this recommendation is likely to be strength-
ened (for future updates or adaptation) by additional research.
An evaluation of the conditions and criteria (and the related
judgments, research evidence, and additional considerations)
that determined the conditional (rather than strong) recommen-
dation will help to identify possible research gaps.
Recommendations
Primary prophylaxis for hospitalized medical patients with
cancer. RECOMMENDATION 1. For hospitalized medical patients
with cancer without VTE, the American Society of Hematology
(ASH) guideline panel suggests using thromboprophylaxis over no
thromboprophylaxis (conditional recommendation, very low certainty
in the evidence of effects Å◯◯◯).
RECOMMENDATION 2. For hospitalized medical patients with cancer
without VTE, in which pharmacological thromboprophylaxis is
used, the ASH guideline panel suggests using LMWH over UFH
(conditional recommendation, low certainty in the evidence of
effects ÅÅ◯◯).
RECOMMENDATION 3. For hospitalized medical patients with cancer
without VTE, the ASH guideline panel suggests using pharmaco-
logical thromboprophylaxis over mechanical thromboprophylaxis
(conditional recommendation, very low certainty in the evidence of
effects Å◯◯◯).
RECOMMENDATION 4. For hospitalized medical patients with
cancer without VTE, the ASH guideline panel suggests using
pharmacological thromboprophylaxis over a combination of
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pharmacological and mechanical thromboprophylaxis (conditional
recommendation, very low certainty in the evidence of effects
Å◯◯◯).
RECOMMENDATION 5. For hospitalized medical patients with
cancer, the ASH guideline panel suggests discontinuing throm-
boprophylaxis at the time of hospital discharge rather than
continuing thromboprophylaxis beyond the discharge date (condi-
tional recommendation, very low certainty in the evidence of effects
Å◯◯◯).
Primary prophylaxis for patients with cancer undergoing
surgery. RECOMMENDATION6. For patients with cancer without VTE
undergoing a surgical procedure at lower bleeding risk, the ASH
guideline panel suggests using pharmacological rather than
mechanical thromboprophylaxis (conditional recommendation, low
certainty in the evidence of effects ÅÅ◯◯).
RECOMMENDATION 7. For patients with cancer without VTE un-
dergoing a surgical procedure at high bleeding risk, the ASH
guideline panel suggests using mechanical rather than pharmaco-
logical thromboprophylaxis (conditional recommendation, low
certainty in the evidence of effects ÅÅ◯◯).
RECOMMENDATION 8. For patients with cancer without VTE
undergoing a surgical procedure at high risk for thrombosis,
except in those at high risk of bleeding, the ASH guideline panel
suggests using a combination of mechanical and pharmacologic
thromboprophylaxis rather than mechanical prophylaxis alone
(conditional recommendation based on low certainty in the evidence of
effects) or pharmacologic thromboprophylaxis alone (condi-
tional recommendation, very low certainty in the evidence of
effects Å◯◯◯).
RECOMMENDATION 9. For patients with cancer undergoing a
surgical procedure, the ASH guideline panel suggests using
LMWH or fondaparinux for thromboprophylaxis rather than UFH
(conditional recommendation, low certainty in the evidence of
effects ÅÅ◯◯).
RECOMMENDATION 10. For patients with cancer undergoing a
surgical procedure, the ASH guideline panel makes no recommen-
dation on the use of VKA or DOAC for thromboprophylaxis,
because there were no studies available.
RECOMMENDATION 11. For patients with cancer undergoing a
surgical procedure, the ASH guideline panel suggests using
postoperative thromboprophylaxis over preoperative thrombopro-
phylaxis (conditional recommendation, low certainty in the evidence
of effects ÅÅ◯◯).
RECOMMENDATION 12. For patients with cancer who had un-
dergone a major abdominal/pelvic surgical procedure, the ASH
guideline panel suggests continuing pharmacological thrombopro-
phylaxis postdischarge rather than discontinuing at the time of
hospital discharge (conditional recommendation, very low certainty
in the evidence of effects Å◯◯◯).
Primary prophylaxis in ambulatory patients with cancer
receiving systemic therapy. RECOMMENDATION 13. For ambula-
tory patients with cancer at low risk for thrombosis receiving
systemic therapy, we recommend no thromboprophylaxis over
parenteral thromboprophylaxis (strong recommendation, moderate
certainty in the evidence of effects ÅÅÅ◯).
For ambulatory patients with cancer at intermediate risk for
thrombosis receiving systemic therapy, the ASH guideline panel
suggests no prophylaxis over parenteral prophylaxis (conditional
recommendation, moderate certainty in the evidence of effects
ÅÅÅ◯).
For ambulatory patients with cancer at high risk for thrombosis
receiving systemic therapy, the ASH guideline panel suggests
parenteral thromboprophylaxis (LMWH) over no thrombopro-
phylaxis (conditional recommendation, moderate certainty in
the evidence of effects ÅÅÅ◯).
RECOMMENDATION 14. For ambulatory patients with cancer re-
ceiving systemic therapy, the ASH guideline panel recommends no
thromboprophylaxis over oral thromboprophylaxis with VKA (strong
recommendation, very low certainty in the evidence of benefits
Å◯◯◯, but high certainty about the harms ÅÅÅÅ).
RECOMMENDATION 15. For ambulatory patients with cancer at low
risk for thrombosis receiving systemic therapy, the ASH guideline
panel suggests no thromboprophylaxis over oral thromboprophylaxis
with a DOAC (apixaban or rivaroxaban) (conditional recommenda-
tion, moderate certainty in the evidence of effects ÅÅÅ◯).
For ambulatory patients with cancer at intermediate risk for
thrombosis receiving systemic therapy, the ASH guideline panel
suggests thromboprophylaxis with a DOAC (apixaban or rivarox-
aban) or no thromboprophylaxis (conditional recommendation,
moderate certainty in the evidence of effects ÅÅÅ◯).
For ambulatory patients with cancer at high risk for thrombosis
receiving systemic therapy, the ASH guideline panel suggests
thromboprophylaxis with a DOAC (apixaban or rivaroxaban) over no
thromboprophylaxis (conditional recommendation, moderate cer-
tainty in the evidence of effects ÅÅÅ◯).
RECOMMENDATIONS 16 AND 17. For multiple myeloma patients
receiving lenalidomide, thalidomide, or pomalidomide-based regi-
mens, the ASH guideline panel suggests using low-dose acetylsa-
licylic acid (ASA) or fixed low-dose VKA or LMWH (conditional
recommendation, low certainty in the evidence of effects ÅÅ◯◯).
Primary prophylaxis for patients with cancer with central
venous catheter. RECOMMENDATION 18. For patients with cancer
and a central venous catheter (CVC), the ASH guideline panel
suggests not using parenteral thromboprophylaxis (conditional
recommendation, low certainty in the evidence of effects
ÅÅ◯◯).
RECOMMENDATION 19. For patients with cancer and a CVC, the
ASH guideline panel suggests not using oral thromboprophylaxis
(conditional recommendation, low certainty in the evidence of
effects ÅÅ◯◯).
Initial treatment (first week) for patients with active cancer
and VTE. RECOMMENDATION 20. For patients with cancer and
VTE, the ASH guideline panel suggests DOAC (apixaban or
rivaroxaban) or LMWH be used for initial treatment of VTE for
patients with cancer (conditional recommendation, very low
certainty in the evidence of effects Å◯◯◯).
RECOMMENDATION 21. For patients with cancer and VTE, we
recommend LMWH over UFH for initial treatment of VTE for
patients with cancer (strong recommendation, moderate certainty in
the evidence of effects ÅÅÅ◯).
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RECOMMENDATION 22. For patients with cancer and VTE, the ASH
guideline panel suggests LMWH over fondaparinux for initial
treatment of VTE for patients with cancer (conditional recommen-
dation, very low certainty in the evidence of effects Å◯◯◯).
Short-term treatment for patients with active cancer (initial
3-6 months). RECOMMENDATION 23. For the short-term treatment of
VTE (3-6 months) for patients with active cancer, the ASH guideline
panel suggests DOAC (apixaban, edoxaban, or rivaroxaban) over
LMWH (conditional recommendation, low certainty in the evidence
of effects ÅÅ◯◯).
RECOMMENDATION 24. For the short-term treatment of VTE (3-6months)
for patients with active cancer, the ASH guideline panel suggests
DOAC (apixaban, edoxaban, or rivaroxaban) over VKA (conditional
recommendation, very low certainty in the evidence of effects Å◯◯◯).
RECOMMENDATION 25. For the short-term treatment of VTE (3-6
months) for patients with active cancer, the ASH guideline panel
suggests LMWH over VKA (conditional recommendation, moderate
certainty in the evidence of effects ÅÅÅ◯).
RECOMMENDATION 26. For patients with cancer and incidental
(unsuspected) pulmonary embolism (PE), the ASH guideline panel
suggests short-term anticoagulation treatment rather than obser-
vation (conditional recommendation, very low certainty in the
evidence of effects Å◯◯◯).
RECOMMENDATION 27. For patients with cancer and subsegmental
PE (SSPE), the ASH guideline panel suggests short-term anti-
coagulation treatment rather than observation (conditional recommen-
dation, very low certainty in the evidence of effects Å◯◯◯).
RECOMMENDATION 28. For patients with cancer and visceral/
splanchnic vein thrombosis, the ASH guideline panel suggests
treating with short-term anticoagulation or observing (conditional
recommendation, very low certainty in the evidence of effectsÅ◯◯◯).
RECOMMENDATION 29. For patients with cancer with CVC-related
VTE receiving anticoagulant treatment, the ASH guideline panel
suggests keeping the CVC over removing the CVC (conditional
recommendation, very low certainty in the evidence of effects Å◯◯◯).
RECOMMENDATION 30. For patients with cancer and recurrent VTE
despite receiving therapeutic LMWH, the ASH guideline panel
suggests increasing the LMWH dose to a supratherapeutic level or
continuing with a therapeutic dose (conditional recommendation,
very low certainty in the evidence of effects Å◯◯◯).
RECOMMENDATION 31. For patients with cancer and recurrent
VTE despite anticoagulation treatment, the ASH guideline panel
suggests not using an inferior vena cava (IVC) filter over using
a filter (conditional recommendation, very low certainty in the
evidence of effects Å◯◯◯).
Long-term treatment (>6 months) for patients with active
cancer and VTE. RECOMMENDATION 32. For patients with active
cancer and VTE, the ASH guideline panel suggests long-term
anticoagulation for secondary prophylaxis (.6 months) rather than
short-term treatment alone (3-6 months) (conditional recommen-
dation, low certainty in the evidence of effects ÅÅ◯◯).
RECOMMENDATION 33. For patients with active cancer and VTE
receiving long-term anticoagulation for secondary prophylaxis,
the ASH guideline panel suggests continuing indefinite anti-
coagulation over stopping after completion of a definitive period
of anticoagulation (conditional recommendation, very low cer-
tainty in the evidence of effects Å◯◯◯).
RECOMMENDATION 34. For patients with active cancer and VTE
requiring long-term anticoagulation (.6months), the ASH guideline
panel suggests using DOACs or LMWH (conditional recommen-
dation, very low certainty in the evidence of effects Å◯◯◯).
Values and preferences
The guideline panel rated mortality, PE, deep venous thrombosis
(DVT), and major bleeding as critical for decision making and placed
a high value on these outcomes and avoiding them with the
interventions that were evaluated.
Explanations and other considerations
These recommendations take into consideration cost and cost-
effectiveness, impact on health equity, acceptability, and feasibility.
Good practice statement 1. Patients with cancer are at
increased risk for VTE, as well as major bleeding. Any consideration
of thromboprophylaxis or treatment for patients with cancer should
be based on an assessment of the patient’s individual risk for
thrombosis and major bleeding after full discussion of the potential
benefits and harms.
Introduction
Aims of these guidelines and specific objectives
The purpose of these guidelines is to provide graded evidence-
based recommendations on the prevention and treatment of VTE
for patients with cancer. Recommendations take into consideration
the strength of the evidence, risks of mortality, VTE, and bleeding,
as well as quality of life, acceptability, and cost considerations.
Through improved provider and patient awareness of the available
evidence and evidence-based recommendations, these guidelines
aim to provide clinical decision support for shared decision
making that will result in a reduction in the frequency of primary
VTE or recurrent VTE, as well as the risk of bleeding complications,
morbidity, and costs leading to improved quality of life and an
enhanced patient experience.
The target audience for the guidelines includes patients, hematologists,
oncologists, general practitioners, internists, and other clinicians
involved in the care of patients with VTE and cancer. These
guidelines will also be of interest to policy-developing local,
national, or international efforts to reduce the incidence of VTE,
morbidity, and mortality, as well as the cost of VTE to patients and
society. This document may also serve as the basis for adaptation
by local, regional, or national guideline panels.
Description of the health problem
Patients with cancer are at greater risk for VTE than is the general
population, resulting in considerable morbidity, mortality, and
costs.13,15-23 Approximately 20% of all cases of VTE occur in
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patients with cancer. In addition, VTE affects up to 20% of patients
with cancer before death and has been reported in up to half of
postmortem examinations of cancer patients. Cancer patients who
develop VTE are at a greater risk for recurrent VTE and early
death.19,23 Although the average risk of VTE for patients with
cancer who are eligible for clinical trials is low, the risk of VTE may
be considerably greater for unselected patients with cancer.13,24-26
The risks of VTE, bleeding, and early mortality among pa-
tients receiving systemic cancer therapy varies by cancer type,
cancer treatment, and other patient-specific factors. Many
cancer therapies, including surgery, chemotherapy, hormonal
therapy, and some targeted cancer treatments, (eg, thalidomide and
lenalidomide) appear to increase the risk of VTE.16,27,28 Further-
more, VTE risk is especially high among certain subgroups,
such as hospitalized patients, those undergoing systemic
cancer therapy, and those with metastatic disease.29-32 Other
factors that have been associated with an increased risk for
VTE include advanced age, male gender, and cancer-related
factors, including cancer type and disease stage. Sites of
cancer with the highest rates of VTE include the pancreas,
kidney, ovary, lung, and stomach.13,15 In addition to antineo-
plastic therapies, certain supportive care measures used in
cancer treatment appear to increase the risk of VTE, including
red blood cell transfusions, as well as erythropoietin-stimulating
agents for managing anemia for patients undergoing cancer
treatment.33 The identification of multiple factors, including
biomarkers, associated with the risk of cancer-associated VTE
has prompted the development of risk scores for predicting VTE
and its complications.14
The occurrence of VTE in patients with cancer may interfere with
planned chemotherapy regimens, increase the risk of mortality,
and result in increased costs compared with patients without
cancer.34,35 However, the impact of VTE extends beyond the
physical and economic; it also has considerable effect on cancer
patients’ quality of life. Several qualitative studies have explored
patients’ experiences of cancer-associated thrombosis, with
consistent reports of VTE causing considerable distress to patients
with cancer and their families.36-38 Some have even reported the
experience of VTE to be more upsetting than that of the cancer.
More than 50% of thrombotic events occur within 3 months of the
cancer diagnosis, a time when most cancer treatments will be
underway. Patients, who are still coming to terms with a recent
cancer diagnosis, often view the occurrence of VTE as a further
threat to life, confirmation of the severity of their condition, and a
poor prognostic sign.
Pharmacologic prophylactic and treatment options for VTE
consist of UFH, LMWHs, fondaparinux (an indirect synthetic
inhibitor of activated factor Xa), VKAs, and DOACs, including
direct thrombin inhibitors (dabigatran) and direct factor Xa
inhibitors (apixaban, edoxaban, and rivaroxaban).30,39 Consider-
ation for the prophylaxis or treatment of VTE for patients with
cancer must always balance the risk of VTE with the increased risk
of bleeding with anticoagulation in patients with cancer. Treatment
decisions should be individualized and take into consideration the
potential consequences of VTE and/or bleeding events (including
mortality, financial cost, quality of life), as well as patient values and
preferences.40 Clinicians should be aware that patients put particular
trust in the opinions of their clinician when deciding on VTE treatment
options.41 As such, it is important to avoid assumptions regarding a
patient’s preferences. Intuitively, one might assume that patients
would prefer an oral anticoagulant rather than a daily injection.
However, data from discrete choice experiments and qualitative
methodologies have shown that cancer patients most value an
anticoagulant that does not interfere with their cancer treatment and
has the best efficacy/safety profile over the convenience of oral
administration.36,41,42
Likewise, patients will have differing views when balancing the risk
of bleeding with a first or recurrent episode of VTE, depending on
their experience and personal values. Sometimes, a high level of
distress may seem to be incongruent with the severity of the
bleeding event or VTE experienced, but it is more a reflection of
what the event means to the patients. Longitudinal data have
demonstrated that PE of minimal symptom burden may cause
similar long-term psychological distress to those experiencing
submassive PE and admission to intensive care.43 This is a
reflection of patients’ understanding of PE, in that they are
potentially life threatening and may occur again without warning.37
Such patients may manifest symptoms similar to posttraumatic
stress disorder.44 Conversely, the distress and long-term psycho-
logical sequelae of experiencing a minor bleed (eg, self-limiting
epistaxis or bruise) may be comparable to those experiencing major
bleeding complications.45 In summary, when engaging in shared
decision-making, it is important to recognize that, for most patients,
the diagnosis of cancer takes primacy over their VTE. It is also
essential to understand that patients may have different values and
priorities than those held by their clinician with respect to goals of
anticoagulation and the risk/benefit ratio of bleeding vs recurrent
VTE. These values and preferencesmay also change over time. Clinical
decision-making tools may help to facilitate meeting patients’ needs
and avoid the risks associated with cognitive dissonance of the
prescribing clinician.
Methods
The guideline panel developed and graded the recommendations
and assessed the certainty in the supporting evidence following
the GRADE approach.5-11 The overall guideline-development
process, including funding of the work, panel formation, manage-
ment of conflicts of interest, internal and external review, and
organizational approval, was guided by ASH policies and procedures
derived from the GIN-McMaster Guideline Development Checklist
(http://cebgrade.mcmaster.ca/guidecheck.html) and was intended to
meet recommendations for trustworthy guidelines by the National
Academy of Medicine (formerly Institute of Medicine) and GIN.1-4
Organization, panel composition, planning,
and coordination
The work of this panel was coordinated with 9 other guideline
panels (addressing other aspects of VTE) by ASH and the McMaster
GRADE Center (funded by ASH under a paid agreement).46 Project
oversight was provided initially by a coordination panel, which reported
to the ASH Committee on Quality, and then by the coordination panel
chair (Adam Cuker) and vice chair (Holger J. Schünemann). ASH
vetted and appointed individuals to the guideline panel. The McMaster
GRADECenter vetted and retained researchers to conduct systematic
reviews of evidence and coordinate the guideline-development
process, including the use of the GRADE approach.46 The
membership of the panels and the GRADE center team is
described in Supplement 1.
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The panel included hematologists, internists, other physicians,
and a pharmacist who all had clinical and research expertise on
the guideline topic, methodologists with expertise in evidence
appraisal and guideline development, and 1 patient represen-
tative. The panel cochairs were content experts. The vice
chair was an internist and an expert in guideline-development
methodology.
In addition to synthesizing evidence systematically, the McMaster
GRADE Center supported the guideline-development pro-
cess, including determining methods, preparing agendas
and meeting materials, and facilitating panel discussions.
The panel’s work was done using Web-based tools (http://
www.surveymonkey.com and https://gradepro.org) and face-
to-face and online meetings.
Guideline funding and management of conflicts
of interest
Development of these guidelines was wholly funded by ASH, a
nonprofit medical specialty society that represents hematologists.
Most members of the guideline panel were members of ASH. ASH
staff supported panel appointments and coordinated meetings but
had no role in choosing the guideline questions or determining the
recommendations.
Members of the guideline panel received travel reimbursement
for attendance at in-person meetings, and the patient represen-
tative was offered, but declined, an honorarium of $200. The
panelists received no other payments. Some researchers who
contributed to the systematic evidence reviews received salary
or grant support through the McMaster GRADE Center. Other
researchers participated to fulfill requirements of an academic
degree or program.
Conflicts of interest of all participants were managed according
to ASH policies based on recommendations of the National
Academy of Medicine47 and GIN.4 At the time of appointment, a
majority of the guideline panel, including 1 of the clinical cochairs
and the vice chair, had no conflicts of interest as defined and
judged by ASH (ie, no current material interest in any commercial
entity with a product that could be affected by the guidelines).
Some panelists disclosed new interests or relationships during
the development process.
Before appointment to the panel, individuals disclosed financial
and nonfinancial interests. Members of the VTE Guideline
Coordination Panel reviewed the disclosures and judged which
interests were conflicts and should be managed. Supplement 2
provides the complete “Disclosure of Interests” forms of all
panel members. In Part A of the forms, individuals disclosed
material interests for 2 years prior to appointment. In Part B, they
disclosed interests that were not primarily financial. Part C
summarizes ASH decisions about which interests were judged
to be conflicts. Part D describes new interests disclosed by
individuals after appointment.
Recusal was also used to manage conflicts of interest. During
all deliberations, panel members with a current direct financial
interest in a commercial entity with any product that could be
affected by the guidelines were recused from making judg-
ments about relevant recommendations.4,48-50 The Evidence-
to-Decision (EtD) framework for each recommendation describes
which individuals were recused from making judgments about each
recommendation.
In 2019, it was discovered that 1 panelist had direct financial
conflicts with affected companies (travel reimbursement, spou-
sal income for consulting) that had not been reported. In 2020,
it was discovered that another panelist had a direct financial
conflict with an affected company (stock ownership). Both
disclosures were made after the recommendations were formed.
Members of the Guideline Oversight Subcommittee reviewed
the guidelines in relation to these late disclosures and agreed
that these conflicts were unlikely to have influenced any of the
recommendations.
None of the McMaster-affiliated researchers who contributed to the
systematic evidence reviews or who supported the guideline-
development process had any current material interest in a
commercial entity with any product that could be affected by the
guidelines. Supplement 3 provides the complete “Disclosure of
Interest” forms of researchers who contributed to these guidelines.
Formulating specific clinical questions and
determining outcomes of interest
The panel used the GRADEpro Guideline Development Tool (https//
gradepro.org)51 and SurveyMonkey (http://www.surveymonkey.com)
to brainstorm and then prioritize the questions described in Table 1.
The panel selected outcomes of interest for each question a
priori, following the approach described in detail elsewhere.52 In
brief, the panel first brainstormed all possible outcomes before
rating their relative importance for decision making following the
GRADE approach. During this rating process, the panel used
definitions of the outcomes (“marker states”) that were de-
veloped for these guidelines. Rating outcomes by their relative
importance can help to focus attention on those considered
most important for clinicians and patients and help to resolve
or clarify potential disagreements. The outcomes rated highly
by the panel and those identified as important based on the
literature reviews were further refined. While acknowledging
considerable variation in the impact on patient outcomes,
the panel considered the following outcomes as critical for clini-
cal decision making across questions: mortality, PE, proximal
DVT, distal DVT, major bleeding (including gastrointestinal [GI]
bleeding), and heparin-induced thrombocytopenia (HIT). Report-
ing of thrombotic events across studies was inconsistent and
variably reported as “any VTE,” “any PE,” “any DVT,” “any
proximal DVT,” and “any distal DVT,” sometimes preceded by
“asymptomatic” or “symptomatic.” Variation in event reporting
resulted in considerable uncertainty for the panel in formulating
recommendations.
Evidence review and development
of recommendations
For each guideline question, the McMaster GRADECenter prepared a
GRADE EtD framework, using the GRADEpro Guideline Development
Tool (https://gradepro.org).5,6,11 The EtD table summarized the results
of systematic reviews of the literature that were updated or performed
for this guideline. The EtD table addressed effects of interventions,
resource utilization (cost-effectiveness), values and preferences
(relative importance of outcomes), equity, acceptability, and
feasibility. The guideline panel reviewed draft EtD tables before,
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during, or after the guideline panel meeting, made suggestions for
corrections, and identified missing evidence. To ensure that recent
studies were not missed, searches (Supplement 4) originally
conducted on 26 February 2016 have been continually updated
for newly published studies. Panel members were also asked to
identify any studies that may have been missed that fulfilled the
inclusion criteria for the individual questions.
Under the direction of the McMaster GRADE Center, researchers
followed the general methods outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (https://handbook.cochra-
ne.org) for conducting updated or new systematic reviews of
intervention effects. When existing reviews were used, judgments
of the original investigators about risk of bias were randomly
checked for accuracy and accepted or conducted de novo if they
were not available or not reproducible. For new reviews, risk of bias
was assessed at the health outcome level using the Cochrane
Collaboration’s risk of bias tool for randomized trials or non-
randomized studies. In addition to conducting systematic reviews
of intervention effects, the researchers searched for evidence
related to baseline risks, values, preferences, and costs and
summarized findings within the EtD frameworks.5,6,11 Subse-
quently, the certainty in the body of evidence (also known as
quality of the evidence or confidence in the estimated effects) was
assessed for each effect estimate of the outcomes of interest
following the GRADE approach based on the following domains:
risk of bias, precision, consistency and magnitude of the estimates
of effects, directness of the evidence, risk of publication bias,
presence of large effects, dose-response relationship, and an
assessment of the effect of opposing plausible residual bias or
confounding. The certainty was categorized into 4 levels ranging
from very low to high and used a wording template to formulate state-
ments that communicate findings combining size and certainty.7-9
When conducting a GRADE assessment, investigators consider the
width of the confidence intervals (CIs) and power of the analysis (ie,
imprecision), as well as all of the other factors to determine the certainty
in the evidence. Thus, the certainty around the point estimate varies
depending on what domains demonstrate shortcomings; with the
exception of imprecision, that certainty interval is not known. For this
reason, when communicating an effect using statements, investigators
should focus on the best estimate and on the certainty in that estimate,
which considers multiple factors. The statements communicate the
size of the effect based on the point estimate in a meta-analysis or on
the summary estimate in a narrative synthesis instead of the CIs.
For each outcome, risk differences were calculated by applying
baseline risk data to the relative effects. Representative cohort data
were used as the source of baseline risk data, when available. When
representative cohort data were not available, median or mean
estimates of baseline risk of the control arms of the included studies
were used. For cases in which more than a single baseline risk
estimate was available, we used several baseline risks (eg, high risk
and low risk). Baseline risk estimates are noted in the article along
with the reference of the study data used. In cases in which the
relative effects of PE or DVT were not available, the relative effects
from VTE were used and applied to baseline risk data for PE or DVT.
In the evidence profiles, baseline risks (ie, control group event rate)
from the trials were reported and included in the meta-analysis. Data
from observational studies were reported in 2 separate rows in the
Evidence Profiles. The risks selected from observational data were
discussed and finalized with panel members prior to the panel
voting on EtDs and formulating recommendations.
Following a 2-day in-person meeting along with subsequent online
communication and conference calls, the panel developed clinical
Table 1. Prioritized clinical questions
Primary prophylaxis for hospitalized medical patients with cancer
Thromboprophylaxis vs no thromboprophylaxis
LMWH vs UFH
Combination of methods vs pharmacological thromboprophylaxis
Mechanical vs pharmacological thromboprophylaxis
Continuation of thromboprophylaxis at home vs discontinuation at time of discharge
Primary prophylaxis for patients with cancer undergoing surgery
Pharmacological vs mechanical thromboprophylaxis
Combination of pharmacologic and mechanical prophylaxis vs mechanical
thromboprophylaxis alone




Preoperative thromboprophylaxis vs immediate postoperative thromboprophylaxis
Extended (continue at home) vs limited (7-10 d; discontinue at the time of discharge)
Primary prophylaxis for ambulatory patients with cancer receiving systemic
therapy
Parenteral thromboprophylaxis vs no thromboprophylaxis
VKA thromboprophylaxis vs no thromboprophylaxis
DOAC thromboprophylaxis vs no thromboprophylaxis
Low-dose ASA thromboprophylaxis vs fixed-dose VKA
Low-dose ASA vs LMWH
Primary prophylaxis for patients with cancer with CVC
Parenteral thromboprophylaxis vs no thromboprophylaxis
Oral thromboprophylaxis vs no thromboprophylaxis








Short-term treatment (3-6 mo) vs observation for patients with cancer and incidental PE
Short-term treatment (3-6 mo) vs observation for patients with cancer and SSPE
Short-term treatment (3-6 mo) vs observation for patients with cancer and visceral/
splanchnic vein thrombosis
Keeping CVC vs removing CVC
Increasing dose to supratherapeutic levels vs continuing with standard therapeutic dose
Adding an IVC filter vs not for patients with cancer and recurrent VTEs, despite
therapeutic anticoagulation treatment
Long-term treatment (>6 mo) for patients with active cancer and VTE
Long-term anticoagulation (.6 mo) vs short-term anticoagulation (3-6 mo)
Continuing indefinite anticoagulation vs stopping after completion of a definitive period
of anticoagulation
DOAC vs LMWH for long-term anticoagulation
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recommendations based on the evidence summarized in the EtD
tables. For each recommendation, the panel took a population
perspective and came to consensus on the following: the certainty
in the evidence, the balance of benefits and harms of the compared
management options, and the assumptions about the values and
preferences associated with the decision. The guideline panel
explicitly took into account the extent of resource use associated
with alternative management options. The panel agreed on the
recommendations (including direction and strength), remarks, and
qualifications by consensus or, in rare instances, by voting (an 80%
majority was required for a strong recommendation), based on the
balance of all desirable and undesirable consequences. The final
guidelines, including recommendations, were reviewed and ap-
proved by all members of the panel. The approach is described in
detail in the accompanying article describing the methods of
development.46
Interpretation of strong and
conditional recommendations
The recommendations are labeled as “strong” or “conditional”
according to the GRADE approach. The term “the guideline panel
recommends” is used for strong recommendations, whereas the term
“the guideline panel suggests” is used for conditional recommenda-
tions. Table 2 provides GRADE’s interpretation of strong and
conditional recommendations by patients, clinicians, health care
policy makers, and researchers.
Document review
Draft recommendations were reviewed by all members of the panel,
revised, and made available online on 17 October 2019 for external
review by stakeholders, including allied organizations, other medical
professionals, patients, and the public. Individuals or organizations
submitted comments. The document was revised to include a newly
published randomized controlled trial (RCT; Caravaggio trial) on
1 April 2020, which changed Recommendation 23.53 On 8
September 2020, the ASH Guideline Oversight Subcommittee
and the ASH Committee on Quality approved that the defined
guideline-development process was followed; on 11 September
2020, the officers of the ASH Executive Committee ap-
proved submission of the guidelines for publication under the
imprimatur of ASH. The guidelines were then subjected to peer
review by Blood Advances.
How to use these guidelines
ASH guidelines are primarily intended to help clinicians make
decisions about diagnostic and treatment alternatives. Other
purposes are to inform policy, education, and advocacy and to
state future research needs. They may also be used by patients.
These guidelines are not intended to serve or be construed as a
standard of care. Clinicians must make decisions on the basis of the
clinical presentation of each individual patient, ideally through a
shared decision-making process that considers the patient’s values
and preferences with respect to the anticipated outcomes of the
chosen option. Decisions may be constrained by the realities of a
specific clinical setting and local resources, including, but not
limited to, institutional policies, time limitations, or availability of
treatments. These guidelines may not include all appropriate
methods of care for the clinical scenarios described. As science
advances and new evidence becomes available, recommendations
may become outdated. Following these guidelines cannot guaran-
tee successful outcomes. ASH does not warrant or guarantee any
products described in these guidelines.
Statements about the underlying values and preferences, as well as
qualifying remarks, accompanying each recommendation are
integral to the guideline and serve to facilitate more accurate
interpretation. Qualifying remarks should never be omitted when
quoting or translating recommendations from these guidelines.
Implementation of the guidelines will be facilitated by forthcoming
interactive decision aids and other implementation tools.54 The use
of these guidelines is also facilitated by the links to the EtD
frameworks and interactive summary of findings tables in each
section.
Recommendations
In the sections that follow, we summarize the evidence behind each
recommendation, along with the following practice statement that
should be considered across all recommendations. Given the
complexity of anticoagulation management for cancer patients with
VTE, the treatment course is divided as follows: initial treatment
(within the first week), short-term anticoagulation (initial 3 to 6
Table 2. Interpretation of strong and conditional recommendations
Implications for: Strong recommendation Conditional recommendation
Patients Most individuals in this situation would want the recommended
course of action, and only a small proportion would not.
The majority of individuals in this situation would want the
suggested course of action, but many would not. Decision aids
may be useful in helping patients to make decisions consistent
with their individual risks, values, and preferences.
Clinicians Most individuals should follow the recommended course of action.
Formal decision aids are not likely to be needed to help individual
patients make decisions consistent with their values and
preferences.
Recognize that different choices will be appropriate for individual
patients and that you must help each patient arrive at a
management decision consistent with their values and
preferences. Decision aids may be useful in helping individuals to
make decisions consistent with their individual risks, values, and
preferences.
Policy makers The recommendation can be adopted as policy in most situations.
Adherence to this recommendation according to the guideline
could be used as a quality criterion or performance indicator.
Policymaking will require substantial debate and involvement of
various stakeholders. Performance measures should assess
whether decision making is appropriate.
Researchers The recommendation is supported by credible research or other
convincing judgments that make additional research unlikely to
alter the recommendation. On occasion, a strong
recommendation is based on low or very low certainty in the
evidence. In such instances, further research may provide
important information that alters the recommendations.
The recommendation is likely to be strengthened (for future
updates or adaptation) by additional research. An evaluation of
the conditions and criteria (and the related judgments, research
evidence, and additional considerations) that determined the
conditional (rather than strong) recommendation will help to
identify possible research gaps.
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months), and long-term anticoagulation (beyond 6 months). This is
consistent with the terminology used in the “Treatment” section of
the ASH VTE Guidelines.
We defined active cancer as (1) nonsquamous cell or basal cell
invasive cancer diagnosed within 6 months before enrollment,
(2) cancer treated within the previous 6 months, (3) recurrent or
metastatic cancer, or (4) active cancer during the study. We
included studies if the majority (.80%) of patients presented
with active cancer, as defined above.
Primary prophylaxis for hospitalized medical patients
with cancer
Should thromboprophylaxis vs no thromboprophylaxis be used for
hospitalized medical patients with cancer without VTE?
Should LMWH vs UFH be used for hospitalized medical patients
with cancer without VTE?
Thromboprophylaxis vs no thromboprophylaxis. SUMMARY OF
THE EVIDENCE. We identified 1 systematic review55 that analyzed
subgroup data from patients with cancer from 3 RCTs (307 patients
with cancer in 5134 study subjects).56-58 Because of a lack of direct
evidence, the guideline panel also included evidence from trials
conducted on hospitalized medical patients from the 2018 ASH
guidelines for management of VTE on prophylaxis for hospitalized and
nonhospitalized medical patients.59
We found 17 systematic reviews that addressed VTE prophylaxis for
medically ill patients,60-76 with 24 studies in these reviews evaluating
thromboprophylaxis vs no prophylaxis in acutely ill medical patients.
All studies included hospitalized acutely ill medical inpatients but
only a small proportion of patients had cancer.57,77-97 The panel
also considered the RCT by Cohen et al57 (ARTEMIS) that
compared fondaparinux against placebo and believed that the
results were similar enough to include fondaparinux along with UFH
and LMWH. The trials of hospitalized medical patients enrolled
mixed populations of patients with acute medical conditions and/or
reduced mobility, including patients with cancer or without cancer.
No trials were identified that evaluated inpatient thromboprophylaxis
in a cancer-specific population. Five included trials reported the
proportion of patients with cancer, which ranged from 5% to 15%
across trials. However, the definition of active cancer differed
across studies, with some including a previous history of cancer in
the definition. Primary thromboprophylaxis may not be appropriate
for all cancer patients. An observational study of advanced
cancer patients (Karnofsky score ,50) admitted to specialist
palliative care units identified that 28% (95% CI, 22-34) of scans
were iliofemoral.98 These patients had minimal attributable symp-
toms and no survival difference vs those with no DVT (mean
survival, 44 days).98 Coupled with a clinically relevant bleeding
rate of 9.8% (95% CI, 8.3-11.6) associated with thrombopro-
phylaxis use in specialist palliative care units, it could be argued
that, in this particular cancer subgroup, the potential for harm
outweighs any potential benefit that thromboprophylaxis may
offer.99 The EtD framework is available at https://guidelines.
ash.gradepro.org/profile/9pXn6iq6qng.
BENEFITS. Parenteral prophylactic anticoagulation (UFH, LMWH, or
fondaparinux) compared with no thromboprophylaxis may reduce
symptomatic proximal DVT, PE, and symptomatic distal DVT, as
well as have little to no effect on mortality; however, the evidence
is very uncertain. The panel judged these effects to be small (for
symptomatic proximal DVT: relative risk [RR], 0.28; 95% CI, 0.06-
1.37; absolute risk reduction [ARR], 22 fewer per 1000; 95% CI,
28 fewer to 11 more per 1000 based on a baseline risk of 3% for
any DVT100; for PE: RR, 0.59; 95% CI, 0.45-0.78; ARR, 4 fewer
per 1000; 95% CI, 2-6 fewer per 1000; for symptomatic distal
DVT: RR, 0.75; 95% CI, 0.17-3.34; ARR, 8 fewer per 1000; 95%
CI, 25 fewer to more per 1000 based on a baseline risk of 3% for
any DVT100; for mortality: RR, 0.97; 95% CI, 0.91-1.04; ARR, 2
fewer per 1000; 95% CI, 6 fewer to 3 more per 1000) based on a
baseline risk of 3% for any DVT.100
HARMS AND BURDEN. Parenteral prophylactic anticoagulation
(UFH, LMWH, or fondaparinux) vs no thromboprophylaxis may
result in little to no difference in major bleeding, but the evidence
is very uncertain and likely results in little to no difference in
thrombocytopenia. The panel judged these effects to be small
(for major bleeding: RR, 1.48; 95% CI, 0.81-2.71; absolute risk
increase [ARI], 3 more per 1000; 95% CI, 1 fewer to 12 more per
1000; for thrombocytopenia: RR, 0.95; 95%CI, 0.47-1.92; ARR, 0 per
1000; 95% CI, 1 fewer to 2 more per 1000), and 3 RCTs reported a
potential small impact on thrombocytopenia (RR, 0.95; 95% CI, 0.47-
1.92; ARR, 0 per 1000; 95% CI, 1 fewer to 2 more per 1000).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as very low owing to the risk of bias,
indirectness, and imprecision of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. Three reports compared
the cost-effectiveness of LMWH to no thromboprophylaxis for
seriously ill medical patients and showed favorable cost-
effectiveness for LMWH.101-103 The panel concluded that there
was no impact on health equity and that the use of any parenteral
anticoagulant (UFH, LMWH, and fondaparinux) was considered
acceptable and feasible.
LMWH vs UFH. SUMMARY OF THE EVIDENCE. We did not find any
systematic reviews that addressed the question. Our systematic
search for RCTs identified 2 analyses104,105 that were conducted
in hospitalized medical patients with cancer. One study is a post
hoc analysis of the CERTIFY trial conducted in hospitalized
Recommendations 1 and 2
For hospitalized medical patients with cancer, the ASH
guideline panel suggests using thromboprophylaxis over no
thromboprophylaxis (conditional recommendation, very low
certainty in the evidence of effects Å◯◯◯). For patients in
whom pharmacological thromboprophylaxis is used, the ASH
guideline panel suggests using LMWH over UFH (conditional
recommendation, low certainty in the evidence of effects
ÅÅ◯◯).
Remarks: The panel acknowledges that some subgroups of
patients may not benefit from VTE prophylaxis if their baseline
risk of VTE is low or the associated risk of major bleeding is
high. This may include patients admitted briefly for elective
chemotherapy and those receiving palliative or end-of-life care.
UFH is generally preferred over LMWH for patients with cancer
and severe renal impairment defined as creatinine clearance
,30 mL/min.
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medical patients.104 This post hoc analysis is a subgroup analysis
of patients with cancer. The second study was not a trial of
patients with cancer specifically; however, it was a large trial
of hospitalized medical patients, some of whom had cancer.105
For the evidence synthesis of this question, we pulled out data
for the patients with cancer. The 2 studies reported on the
effect of LMWH vs UFH on mortality:104,105 1 study on
symptomatic DVT104 and 1 study on major bleeding.105 The
EtD framework is available at https://guidelines.ash.grade-
pro.org/profile/86dbRedTHj8.
BENEFITS. Compared with UFH, LMWHmay reduce mortality slightly
and may result in little or no difference in PE and symptomatic DVT,
and the panel judged the effects to be small (for mortality: RR, 0.52;
95% CI, 0.18-1.53; ARR, 21 fewer per 1000; 95% CI, 36 fewer to
23 more per 1000; for PE: RR, 0.33; 95% CI, 0.01-8.04; ARR,
0 fewer per 1000; 95% CI, 0 fewer to 1 more per 1000 using a
baseline risk of 0.01%106; for symptomatic DVT: RR, 0.98; 95% CI,
0.06-15.44; ARR, 1 fewer per 1000; 95%CI, 28 fewer to 433 more
per 1000 using a baseline risk of 3%).101
HARMS AND BURDEN. Compared with UFH, LMWH may result in little to
no difference in major bleeding, and the panel judged the impact to be
trivial (RR, 1.06; 95% CI, 0.07-16.78; ARI, 2 more per 1000; 95% CI,
24 fewer to 410 more per 1000 using a baseline risk of 2.6%).106
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as low owing to serious imprecision of the
estimates.
OTHERETDCRITERIA ANDCONSIDERATIONS. The panel agreed that greater
health care provider time is required with UFH, that multiple
injections per days may also lead to dosing errors and disposal
hazard, and that the drug acquisition cost of LMWH is higher than
that of UFH. However, the overall resources required were judged
negligible, and no direct data for cost-effectiveness were available.
The panel concluded that there was no impact on health equity, and
acceptability was judged to be variable. Utilization of LMWH was
considered feasible because it is current practice.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
panel determined that there is low certainty in the evidence for a
net health benefit from using anticoagulation prophylaxis for
hospitalized medical patients with cancer. Nevertheless, an overall
favorable benefit over harms seems to favor thromboprophylaxis
in this setting. A conditional, rather than strong, recommendation
was based on the low certainty in the evidence. As well, the panel
acknowledges that some subgroups of patients may not benefit
(eg, patients at the end of life) from VTE prophylaxis if their baseline
risk of VTE is low or the associated risk of major bleeding is high.
The panel noted that hospitalized medical patients with cancer are
considered at greater risk for VTE than are nonhospitalized patients
with cancer.107 By reducing the risk of VTE for hospitalized patients
with cancer, thromboprophylaxis over no prophylaxis is probably
cost-effective. Although many criteria did not favor either (eg,
acquisition cost, health care provider time), of the 2 alternatives (ie,
UFH and LMWH), the overall benefits vs harm ratio favored LMWH.
However, UFH is generally preferred over LMWH for the patient
with cancer with severe renal impairment (defined as creatinine
clearance ,30 mL/min).
The panel believed that implementation of the intervention
might be facilitated by prompting the evaluation of eligibility for
thromboprophylaxis for hospitalized medical patients with
cancer. Hospitals caring for patients with cancer should
potentially consider monitoring for compliance with recom-
mendations of the use of appropriate thromboprophylaxis in
this setting. Continuous medical education should be provided
routinely related to this recommendation.
The panel agreed that further research is needed in hospitalized
medical patients with cancer. More information is needed on the
optimal choice, dosing, and duration of parenteral anticoagulation
to prevent VTE for hospitalized patients with cancer. Further
information is also needed on the dosing of anticoagulation for
obese patients, underweight patients, patients with hematological
malignancies or undergoing stem cell transplantation, and patients
with renal disease.
Should mechanical thromboprophylaxis be used instead of or in
addition to pharmacological prophylaxis for hospitalized medical
patients with cancer without VTE?
Combination of methods vs pharmacological
thromboprophylaxis. SUMMARY OF THE EVIDENCE. No systematic
review or clinical trial in hospitalized patients with cancer was
identified that addressed these questions. The guideline panel
considered evidence from trials conducted in hospitalized
medical patients from the “ASH 2018 Guidelines for Manage-
ment of VTE: Prophylaxis for Hospitalized and Nonhospitalized
Medical Patients.”59 Trials were identified from 1 systematic
review that included patients with trauma108 and 1 systematic
review that included patients with stroke.109 We identified 1
additional clinical trial when updating these reviews.110 The 4 trials
reported the effect of the combination of mechanical prophylaxis
(mechanical devices [Arthroflow device passively extends and
plantarflexes],111 pulsatile foot pumps,112 and intermittent pneumatic
compression devices [IPCs]113) and pharmacological thrombopro-
phylaxis (LMWH) compared with pharmacological thromboprophylaxis
alone on mortality and PE,111-113 2 trials on proximal and distal DVT,111
and 2 trials reported on major bleeding.112 There are no data on
graduated compression stockings (GCSs) in this setting. The EtD
framework is available at https://guidelines.ash.gradepro.org/profile/
Ou7MNNaDgFM.
Recommendations 3 and 4
For hospitalized medical patients with cancer without VTE, the
ASH guideline panel suggests using pharmacological throm-
boprophylaxis over mechanical thromboprophylaxis (condi-
tional recommendation, very low certainty in the evidence of
effectsÅ◯◯◯) and over a combination of pharmacological and
mechanical thromboprophylaxis (conditional recommendation,
very low certainty in the evidence of effects Å◯◯◯).
Remarks: Hospitalized patients with cancer without VTE at
high risk for major bleeding may be considered for mechanical
thromboprophylaxis without pharmacologic thromboprophy-
laxis. A combination of pharmacological and mechanical pro-
phylaxis may also be considered for selected hospitalized
medical patients with cancer who are considered at very high
risk for VTE (eg, patients with cancer with sustained and pro-
longed immobilization).
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BENEFITS. The use of combined methods compared with pharma-
cological thromboprophylaxis may reduce mortality, PE, and
proximal/distal DVT, but the evidence is very uncertain, and
the panel judged the effects to be small (for mortality: RR, 0.99;
95% CI, 0.81-1.22; ARR, 1 fewer per 1000; 95% CI, 24 fewer to
27 more per 1000; for PE: RR, 0.69; 95% CI, 0.30-1.58; ARR,
3 fewer per 1000; 95% CI, 8 fewer to 6 more per 1000; for
proximal DVT: RR, 0.37; 95% CI, 0.05-2.73; ARR, 38 fewer per
1000; 95% CI, 57 fewer to 104 more per 1000; for distal DVT:
RR, 0.61; 95% CI; 0.18-2.11; ARR, 7 fewer per 1000; 95% CI,
14 fewer to 19 more per 1000).
HARMS AND BURDEN. Combination method vs pharmacological
thromboprophylaxis may increase major bleeding, but the
evidence is very uncertain, and the panel judged the effect to
be trivial (for major bleeding: RR, 2.83; 95% CI, 0.30-26.70;
ARI, 19 more per 1000; 95% CI, 7 fewer to 265 more per 1000).
The panel concluded that the risk of major bleeding is unlikely to be
increased by adding mechanical prophylaxis to anticoagulation.
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as very low owing to serious indirectness and very
serious imprecision of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel agreed that the
cost, adherence, and proper application of the devices for different
mechanical methods would vary. The costs are considered
negligible for GCSs but moderate to high for IPCs. However,
no direct data for cost-effectiveness were available. The panel
concluded that there is a cost increase with adding mechanical
prophylaxis that will vary across settings, along with the uncertainty
in the net benefit vs harm.
The panel agreed that the impact on health equity is likely to vary,
depending on the availability of mechanical prophylaxis methods.
The panel concluded that, for all stakeholders, IPCs will likely be
less acceptable to many patients and caregivers than GCSs, that
GCSs are feasible to use, and that IPCs may not be feasible in
some settings.
Mechanical vs pharmacological thromboprophylaxis.
SUMMARY OF THE EVIDENCE. We did not find any systematic reviews
or trials addressing this question. Because of the lack of direct
evidence, the guideline panel decided to include evidence from 8
trials conducted in the general population from the “ASH 2018
Guidelines for Management of VTE: Prophylaxis for Hospitalized
and Nonhospitalized Medical Patients.”59 Our systematic search
for trials identified 2 trials conducted on medical acutely or critically ill
patients.114,115 Because of the lack of direct evidence, the guideline
panel decided to also include indirect evidence available from trials
conducted on trauma patients. We found 1 systematic review
that provided evidence on patients with trauma.108 Seven
trials reported the effect of mechanical thromboprophylaxis vs
pharmacological thromboprophylaxis on mortality,113,115-120 7
trials reported on PE,113-119 3 trials reported on symptomatic
DVT,114,118,119 and 7 trials reported onmajor bleeding.114,116-121 The
EtD framework is available at https://guidelines.ash.gradepro.org/
profile/ne1WlYrq2RE.
BENEFITS. Mechanical vs pharmacological thromboprophylaxis may
reduce mortality and major bleeding but the evidence is very
uncertain, particularly with regard to its applicability to nonsurgical
patients with cancer; the panel judged the effects to be trivial
(for mortality: RR, 0.95; 95%CI, 0.42-2.16; ARR, 1 fewer per 1000;
95% CI, 11 fewer to 21 more per 1000; for major bleeding: RR,
0.87; 95% CI, 0.25-3.08; ARR, 1 fewer per 1000; 95% CI, 6 fewer
to 16 more per 1000).
HARMS AND BURDEN. Mechanical vs pharmacological thromboprophy-
laxis may increase PE and symptomatic DVT but the evidence is
uncertain, and the panel judged the effects to be small (for PE: RR,
1.54; 95% CI, 0.48-4.93; ARI, 5 more per 1000; 95% CI, 5 fewer
to 39 more per 1000; for symptomatic DVT: RR, 2.20; 95% CI,
0.22-22.09; ARI, 36 more per 1000; 95%CI, 23 fewer to 633 more
per 1000).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as very low owing to serious risk of bias, very
serious indirectness, and very serious imprecision of the estimates.
The panel had very important concerns about indirectness, in
particular because of the potential heightened risk of major bleeding
in trauma patients receiving pharmacological thromboprophylaxis
compared with medically ill hospitalized patients with cancer and
the potential for mechanical devices to limit mobility of hospitalized
patients, further increasing the risk of VTE.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel considered that
the costs are likely to be negligible. However, cost, adherence, and
proper application of the devices of mechanical prophylaxis will
likely vary (eg, by device [IPC vs GCS] and setting). In-hospital
LMWH costs are lower than mechanical prophylaxis but will also
vary between settings (eg, country). Based on the available
evidence, the panel concluded that the cost-effectiveness
probably favors pharmacological thromboprophylaxis. The con-
siderations for equity, acceptability, and feasibility are the same
as for the comparison of combined prophylaxis vs mechanical or
pharmacological prophylaxis alone.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. For the
comparison of combination vs pharmacological thromboprophy-
laxis, the panel determined, based on very low certainty in the
evidence, that the balance of effects probably does not favor the
intervention or the comparison and that cost-effectiveness
probably favors pharmacological prophylaxis alone. However, a
combination of pharmacological and mechanical prophylaxis may
be considered for selected hospitalized medical patients with
cancer who are considered at very high risk for VTE (eg, patients
with cancer with sustained and prolonged immobilization).
For the comparison of mechanical vs pharmacological thrombo-
prophylaxis, the panel determined that there is very low certainty
in the evidence for a net health harm from using mechanical
prophylaxis for hospitalized medical patients with cancer and
concluded that the balance probably favors pharmacological
prophylaxis. However, patients at high risk for major bleeding
may be considered for mechanical, rather than pharmacological,
thromboprophylaxis.
The panel believed that additional research is needed to di-
rectly evaluate the potential benefits and harms of mechanical
thromboprophylaxis, alone or in combination with pharmacolog-
ical thromboprophylaxis, for hospitalized medical patients with
cancer considered at high risk for VTE. The panel believed that
implementation of the recommendation might potentially be
facilitated by prompting the evaluation of eligibility for thrombopro-
phylaxis for hospitalized medical patients with cancer. Prompting
may be based on different technologies, but additional studies
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assessing the optimal implementation strategy are warranted.
Hospitals caring for patients with cancer should potentially consider
monitoring for compliance with recommendations on the use of
appropriate thromboprophylaxis in this setting.
Should thromboprophylaxis for hospitalized medical patients with
cancer be continued after discharge or should thromboprophylaxis
be discontinued at time of discharge?
Continuation of thromboprophylaxis at home vs discont-
inuation at time of discharge. SUMMARY OF THE EVIDENCE.
No systematic review or individual clinical trial was found that
addressed this question. Because of the lack of direct evidence, the
guideline panel decided to include evidence from 4 trials conducted
on hospitalized medical patients from the “ASH 2018Guidelines for
Management of VTE: Prophylaxis for Hospitalized and Nonhospi-
talized Medical Patients.”59 One systematic review122 included 3
RCTs that provided evidence related to this question.123-125 An
update of the systematic review identified 2 additional studies that
fulfilled the inclusion criteria.126,127 All studies included acutely and
critically ill medical patients. All trials used DOACs, with the
exception of the EXCLAIM trial, which assessed LMWH. Three trials
included data on the prevalence of patients with active cancer
(range, 1.5-7.3%).123-125 None of the trials included cancer
subgroup analyses. Five studies reported the effect of extended
pharmacological thromboprophylaxis vs cessation at discharge on
mortality and major bleeding,123-127 4 studies reported on PE and
symptomatic DVT,123,124,126,127 and 1 study assessed the risk of
developing HIT.125 The EtD framework is available at https://
guidelines.ash.gradepro.org/profile/Wem_cUuhIog.
BENEFITS. Continuation of thromboprophylaxis at home vs discon-
tinuation at time of hospital discharge may reduce symptomatic
DVT, as well as mortality and PE, but the evidence is very uncertain,
and the panel judged the effects to be trivial (for symptomatic DVT:
RR, 0.54; 95% CI, 0.32-0.91; ARR, 3 fewer per 1000; 95% CI, 1-4
fewer per 1000 using a baseline risk of 0.74%123; for mortality: RR,
0.97; 95% CI, 0.87-1.08; ARR, 1 fewer per 1000; 95% CI, 4 fewer
to 3 more per 1000; for PE: RR, 0.63; 95% CI, 0.39-1.03; ARR, 3
fewer per 1000; 95% CI, 0-5 fewer per 1000 using a baseline risk
of 0.74%).123
HARMS AND BURDEN. Continuation of thromboprophylaxis at home vs
discontinuation may increase the risk of major bleeding and may
increase the risk of HIT, but the evidence is very uncertain, and the
panel judged the effect to be trivial (for major bleeding: RR, 2.04;
95% CI, 1.42-2.91; ARI, 3 more per 1000; 95% CI, 1-6 more per
1000; for HIT: RR, 3.01; 95% CI, 0.12-73.93, with only 1 reported
HIT event occurring in the extended prophylaxis group [n5 2975]
and 0 events occurring in the group discontinuing prophylaxis at
discharge [n 5 2988]).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as very low owing to indirectness and
imprecision of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel determined that
there is very low certainty in the evidence for a net health benefit
from discontinuation at time of discharge (over continuation of
thromboprophylaxis at home) in hospitalized medical patients with
cancer and concluded that the balance probably favors discontin-
uation. The panel concluded that, based on the available evidence,
the cost-effectiveness also probably favors discontinuation of
thromboprophylaxis at time of discharge.
Continuation of thromboprophylaxis could cause inequity because
of concerns about cost and/or the ability to self-inject. In addition,
some patients might find having to continue anticoagulation
(especially if given parenterally) at home unacceptable. Health care
professionals would need to monitor and respond to complications
(major bleeding) with continued anticoagulation. The trade-off
between added cost of drug and possibly fewer rehospitalizations
for VTE will probably not have an overall beneficial net effect;
however, formal cost-effectiveness studies are not available.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS.
The conditional recommendation for discontinuation of thrombo-
prophylaxis at the time of hospital discharge over continuation at
home for medical patients with cancer without VTE is due to a
balance that probably favors discontinuation, in the context of very
low certainty evidence, indirectness, moderate costs, and cost-
effectiveness. Ambulatory patients with cancer receiving systemic
therapy and at high risk for thrombosis are an exception. If
thromboprophylaxis were continued beyond discharge, monitoring
might be required (eg, platelet counts, bleeding, affordability).
The panel agreed that further research on risk stratification for
selection of high-risk subgroups for continued thromboprophylaxis
beyond hospitalization is needed.
Primary prophylaxis for patients with cancer
undergoing surgery
Should pharmacological thromboprophylaxis vs mechanical throm-
boprophylaxis vs a combination of both be used for thrombopro-
phylaxis for patients with cancer undergoing a surgical procedure?
Recommendation 5
For hospitalized medical patients with cancer, the ASH
guideline panel suggests discontinuing thromboprophylaxis at
the time of hospital discharge rather than continuing throm-
boprophylaxis beyond the discharge date (conditional recom-
mendation, very low certainty in the evidence of effectsÅ◯◯◯).
Remarks: Continuation of thromboprophylaxis following dis-
charge may be considered for selected ambulatory patients
with cancer receiving systemic treatment and whose risk of
VTE is considered to outweigh the risk of bleeding.
Recommendations 6, 7, and 8
For patients with cancer undergoing a surgical procedure at
low bleeding risk, the ASH guideline panel suggests using
pharmacological rather than mechanical thromboprophylaxis
(conditional recommendation, low certainty in the evidence of
effects ÅÅ◯◯).
For patients at high bleeding risk, the ASH guideline panel
suggests using mechanical rather than pharmacological throm-
boprophylaxis (conditional recommendation, low certainty in the
evidence of effects ÅÅ◯◯).
For patients at high risk for thrombosis, with the exception of
those also at high risk for bleeding, the ASH guideline panel
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Pharmacological vs mechanical thromboprophylaxis.
SUMMARY OF THE EVIDENCE. We identified 4 systematic reviews
addressing this question.128-131 From these reviews, we identified
3 RCTs that fulfilled our inclusion criteria and measured outcomes
relevant to this question.132-134 Our systematic search of RCTs
identified 3 additional studies not included in the previous reviews
that fulfilled the inclusion criteria.135-137 Ten included trials reported
that the proportion of patients with cancer ranged from 4% to
100% across trials. However, the site and stage of cancer included
varied across trials. Types of surgery included in these studies
were pelvic,133,134,136 abdominal,135,137 and neurosurgical.132 Of
the studies comparing pharmacological thromboprophylaxis with
mechanical thromboprophylaxis, 2 studies reported the effect on
mortality,132,137 3 studies reported the effect on any PE,133,136,137
5 studies reported the effect on symptomatic DVT,133-137 2 studies
reported the effect on major bleeding,132,137 and 1 study reported
on reoperation for bleeding.137 The EtD framework is available at
https://guidelines.ash.gradepro.org/profile/pfhapwI0BGM.
BENEFITS. For patients at low and at high risk for thrombosis,
pharmacological prophylaxis compared with mechanical prophy-
laxis results in little to no difference in mortality and reoperation for
bleeding, but the evidence is very uncertain (for mortality: RR, 1.05;
95% CI, 0.07-15.69; ARR, 0 fewer per 1000; 95% CI, 7 fewer to
103 more per 1000 using a baseline risk of 0.7%138; for reoperation
for bleeding: RR, 0.12; 95% CI, 0.00-2.84 with only 1 report-
ed event occurring in the mechanical thromboprophylaxis group
(n 5 38) and no events occurring in the pharmacological thrombopro-
phylaxis group (n 5 109).
For patients at low risk for thrombosis,138 the panel determined the
benefits of pharmacological prophylaxis over mechanical prophylaxis
to be small with respect to thrombosis outcomes. Pharmacological
prophylaxis may reduce any PE and any DVT, and it may increase
symptomatic DVTs compared with mechanical prophylaxis, but the
evidence is very uncertain (for any PE: RR, 0.13; 95% CI, 0.01-2.38;
ARR, 2 fewer per 1000; 95% CI, 2 fewer to 3 more per 1000 using a
baseline risk of 0.2%138; for any DVT: RR, 0.29; 95% CI, 0.03-2.80;
ARR, 1 fewer per 1000; 95% CI, 2 fewer to 4 more per 1000 using a
baseline risk of 0.2%138; for symptomatic DVT: RR, 1.65; 95% CI,
0.50-5.47; ARI, 1 more per 1000; 95% CI, 1 fewer to 9 more per
1000 using a baseline risk of 0.2%).138
For patients at high risk for thrombosis, the panel determined the
benefits to be moderate. Pharmacological thromboprophylaxis may
reduce any DVT and any PE, and it may increase symptomatic
DVTs, but the evidence is very uncertain (for any DVT: RR, 0.29;
95% CI, 0.03-2.80; ARR, 44 fewer per 1000; 95% CI, 60 fewer to
110 more per 1000 using a baseline risk of 6.1%; for any PE: RR,
0.13; 95% CI, 0.01-2.38; ARR, 18 fewer per 1000; 95% CI, 20 fewer
to 28 more per 1000 using a baseline risk of 2.1%; for symptomatic
DVT: RR, 1.65; 95%CI, 0.50-5.47; ARI, 10 more per 1000; 95%CI, 8
fewer to 68 more per 1000 using a baseline risk of 1.5%).
HARMS AND BURDEN. Among patients at low risk for bleeding,
pharmacological prophylaxis may increase major bleeding; the
panel determined the harms to be moderate (RR, 2.52; 95% CI,
0.45-14.13; ARI, 12 more per 1000; 95%CI, 4 fewer to 105 more per
1000 using a baseline risk of 0.6%).138 Among patients at high risk for
bleeding, pharmacological prophylaxis may increase major bleeding,
but the evidence is very uncertain (RR, 2.52; 95%CI, 0.45-14.13; ARI,
10 more per 1000, 95% CI, 3 fewer to 82 more per 1000 using a
baseline risk of 0.8%.138 Although the panel judged the harms to
be small, the panel was concerned about potentially higher risks and
higher morbidity of bleeding associatedwith some types of surgery (eg,
neurosurgery with a nonsignificant trend toward an increased risk for
bleeding with the addition of pharmacological thromboprophylaxis).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as very low owing to serious risk of bias and very
serious imprecision of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel considered that
the costs of either strategy were negligible. However, the cost of
mechanical thromboprophylaxis will vary depending on the device
(eg, IPC vs GCS) and setting. The cost-effectiveness probably
favors mechanical thromboprophylaxis given the results of the
evaluations in the surgical setting.139-144 Equity, acceptability, and
feasibility are also likely to vary. Pharmacological thromboprophy-
laxis is likely to be acceptable; however, the acceptability of
mechanical thromboprophylaxis is likely to vary depending on the
type of device used (GCSs are feasible to use, but IPCs may be less
feasible in some environments).
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
panel concluded that the primary factor to consider when
choosing between mechanical and pharmacological thrombopro-
phylaxis is the risk of major bleeding. The panel made a conditional
recommendation for using pharmacological rather than mechan-
ical thromboprophylaxis for patients with cancer without VTE at
lower bleeding risk, as a result of a balance of effects that favors
the intervention. The panel made a conditional recommendation
for using mechanical rather than pharmacological thrombopro-
phylaxis for patients with a higher risk for bleeding as a result of a
balance of effects that favors mechanical thromboprophylaxis.
Combination of pharmacologic and mechanical prophylaxis
vs mechanical thromboprophylaxis alone. SUMMARY OF THE
EVIDENCE. We identified 1 systematic review addressing this ques-
tion.128 From this review, we identified 3 eligible RCTs that fulfilled our
inclusion criteria and measured outcomes relevant to this
context.132,145,146 Our systematic search of RCTs identified 4
additional trials not included in the previous review that fulfilled
the inclusion criteria.147-150 Ten included trials reported the
proportion of patients with cancer (range, 4-100% across trials).
However, the site and stage of cancer included varied across
trials. The different types of surgeries included in these
trials were neurosurgical,132,145,146 abdominal,147,150 thoracic,149
suggests using a combination of mechanical and pharmaco-
logic thromboprophylaxis rather than mechanical prophylaxis
alone (conditional recommendation based on low certainty in
the evidence of effects) or pharmacologic thromboprophylaxis
alone (conditional recommendation, very low certainty in the
evidence of effects Å◯◯◯).
Remarks: Early ambulation should be favored over mechanical
thromboprophylaxis when indicated. In situations in which there
is a high risk for thrombosis and major bleeding, mechanical
thromboprophylaxis alone is suggested until the patient is no
longer at high risk for major bleeding, then adding pharmaco-
logical thromboprophylaxis is suggested.
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and pelvic.148 Of these studies comparing a combination of
mechanical and pharmacological thromboprophylaxis with mechan-
ical thromboprophylaxis, 4 studies reported the effect on
mortality,132,145,146,148 6 studies reported the effect on PE,145-150
5 studies reported the effect on symptomatic DVT,145-148,150 and 5
studies reported the effect on major bleeding.145-148,150 We
identified an additional study through search alerts; however, it
was not included because it was not believed that it would modify
the findings substantially.151 The EtD framework is available at
https://guidelines.ash.gradepro.org/profile/0v0MnziCyH0.
BENEFITS. The panel agreed that the effects vary according to the
baseline risk of thrombosis. For patients at low risk for thrombosis,
the panel determined the effects to be small. For patients at high risk
for thrombosis, the panel determined the effects benefits to be
moderate.
For patients at low risk for thrombosis, combination of mechanical
and pharmacological prophylaxis compared with mechanical pro-
phylaxis may result in little to no difference in any PE, symptomatic
PE, symptomatic DVT, and any DVT (for any PE: RR, 0.68; 95% CI,
0.21-2.26; ARR, 1 fewer per 1000; 95% CI, 2 fewer to 3 more per
1000 using a baseline risk of 0.2%138; for symptomatic PE: RR,
0.24; 95% CI, 0.05-1.12; ARR, 2 fewer per 1000; 95% CI, 0-2
fewer per 1000 using a baseline risk of 0.2%138; for symptomatic
DVT: RR, 0.22; 95% CI, 0.06-0.89; ARR, 2 fewer per 1000; 95%
CI, 0-2 fewer per 1000 using a baseline risk of 0.2%138; for any
DVT: RR, 0.54; 95% CI, 0.37-0.78; ARR, 1 fewer per 1000; 95%
CI, 0-1 fewer per 1000 using a baseline risk of 0.2%).138
For patients at high risk for thrombosis, combination of mechanical
and pharmacological prophylaxis compared with mechanical
prophylaxis alone may reduce any PE and symptomatic PEs, and
it reduces symptomatic DVTs and any DVT (for any PE: RR, 0.68;
95% CI, 0.21-2.26; ARR, 4 fewer per 1000; 95% CI, 10 fewer to
15 more per 1000 using a baseline risk of 1.2%; for symptomatic
PE: RR, 0.24; 95% CI, 0.05-1.12; ARR, 13 fewer per 1000;
95% CI, 16 fewer to 2 more per 1000 using a baseline risk of
1.7%; for symptomatic DVT: RR, 0.22; 95% CI, 0.06-0.89; ARR,
10 fewer per 1000; 95%CI, 1-12 fewer per 1000 using a baseline
risk of 1.3%; for any DVT: RR, 0.54; 95% CI, 0.37-0.78; ARR, 55
fewer per 1000; 95% CI, 26-75 fewer per 1000 using a baseline
risk of 11.9%).
HARMS AND BURDEN. Combination of mechanical and pharmacolog-
ical prophylaxis compared with mechanical prophylaxis alone
likely increases mortality slightly and may increase major
bleeding slightly (for mortality: RR, 1.36; 95% CI, 0.56-3.30;
ARI, 3 more per 1000; 95% CI, 3 fewer to 16 more per 1000
using a baseline risk of 0.7%138; for major bleeding: RR, 1.88;
95% CI, 0.71-4.99; ARI, 7 more per 1000; 95% CI, 2 fewer to 32
more per 1000 using a baseline risk of 0.8%).138 Although the
panel judged the harms to be small, the panel was concerned
about the higher risk for bleeding and mortality associated with
some types of surgery (eg, neurosurgery with a nonsignificant
trend toward an increased risk for bleeding with the addition of
pharmacological thromboprophylaxis).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as low owing to very serious imprecision.
OTHER ETD CRITERIA AND CONSIDERATIONS. The balance of benefits vs
harms varies according to the baseline risk of thrombosis.
For lower-risk patients, the balance does not favor combination
thromboprophylaxis or mechanical thromboprophylaxis alone.
For higher-risk patients, the balance probably favors the combina-
tion of mechanical and pharmacologic thromboprophylaxis.
Overall, the panel considered that the costs are likely to be
negligible. However, the cost of mechanical thromboprophylaxis will
vary depending on the device (eg, IPC vs GCS) and setting. The
cost-effectiveness probably favors the combination, given the
results of the evaluations in the surgical setting.152 Equity,
acceptability, and feasibility also are likely to vary. Health equity is
likely to vary, depending on the availability of mechanical
prophylaxis methods. Although pharmacological thrombopro-
phylaxis is likely to be acceptable, the acceptability of mechanical
thromboprophylaxis is likely to vary depending on the type of
device used (GCSs are feasible to use, but IPCs may not be
feasible in some settings).
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
panel concluded that the primary factor related to the choice
between combined thromboprophylaxis methods and mechanical
thromboprophylaxis alone is the risk of thrombosis. The panel made
a conditional recommendation for using combination methods
rather than mechanical thromboprophylaxis for patients with cancer
without VTE at high risk for thrombosis, as a result of a balance of
effect that probably favors the intervention. The panel made a
conditional recommendation for mechanical thromboprophylaxis
rather than combination thromboprophylaxis for patients with a
lower risk for thrombosis or a high risk for bleeding. The panel did
not identify high-priority future research questions.
Combination of pharmacologic and mechanical prophylaxis
vs pharmacological thromboprophylaxis alone. SUMMARY OF
THE EVIDENCE. We identified 7 systematic reviews addressing this
question.130,153-160 From these reviews, we identified 19 studies
that fulfilled our inclusion criteria and measured outcomes relevant
to this context.112,132,135,161-176 Seven included trials reported the
proportion of patients with cancer (range, 4-50% across trials).
However, the site and stage of cancer included varied across trials.
We identified 1 additional clinical trial when updating these
reviews.110 Although the trial compared the combination of
pharmacological and mechanical prophylaxis with pharmacological
thromboprophylaxis alone in patients admitted to the intensive care
unit, the panel decided to include the trial given that it was a recent
large RCT including high-risk patients and assessing IPCs as
mechanical thromboprophylaxis. Eight studies reported the effect
of the combination of pharmacological and mechanical thrombo-
prophylaxis compared with pharmacological thromboprophylaxis
alone on risk of mortality.110,112,132,161-163,165,170 Eleven studies
reported the effect on the development of symptomatic
PEs,110,112,132,135,163,165,167-170,176 and 6 studies reported the
effect on the development of any PE.161,162,166,171,175,176 Nine
studies reported data on any proximal DVT.110,112,135,162,166,171-173
Eight studies reported data on any distal DVT.112,134,165,168,169,173-175
Seven studies reported the effect of combination pharmaco-
logical and mechanical thromboprophylaxis compared with
pharmacological thromboprophylaxis alone on the risk of major
bleeding,110,112,132,162,167,170,171 and 2 studies reported the effect
on the risk of reoperation.165,176 The EtD framework is available at
https://guidelines.ash.gradepro.org/profile/czqor6q_zWY.
BENEFITS. Combination thromboprophylaxis compared with
pharmacological thromboprophylaxis may reduce symptomatic
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PEs, any PE, any proximal DVT, and any distal DVT, and it may
increase symptomatic distal DVTs, but the evidence is very uncertain.
Combination thromboprophylaxis compared with pharmacological
thromboprophylaxis alone may have little to no effect on mortality, but
the evidence is very uncertain. The panel judged these effects to be
small (for symptomatic PE: RR, 0.47; 95% CI, 0.31-0.71; ARR, 12
fewer per 1000; 95%CI, 7-16 fewer per 1000; for any PE: RR, 0.67;
95% CI, 0.33-1.35; ARR, 4 fewer per 1000; 95% CI, 8 fewer to 4
more per 1000; for any proximal DVT: RR, 0.73; 95% CI, 0.45-1.17;
ARR, 13 fewer per 1000; 95% CI, 27 fewer to 8 more per 1000; for
any distal DVT: RR, 0.81; 95% CI, 0.52-1.26; ARR, 12 fewer per
1000; 95%CI, 31 fewer to 17more per 1000; for symptomatic distal
DVT: RR, 1.99; 95% CI, 0.35-11.33; ARI, 9 more per 1000; 95%CI,
6 fewer to 96 more per 1000; for mortality: RR, 0.98; 95% CI, 0.80-
1.20; ARR, 1 fewer per 1000; 95% CI, 9 fewer to 9 more per 1000
using a baseline risk of 4.7%).
HARMS AND BURDEN. Combination thromboprophylaxis compared
with pharmacological thromboprophylaxis alone may increase major
bleeding, but the evidence is very uncertain. The panel judged these
effects to be trivial (for major bleeding: RR, 1.05; 95% CI, 0.32-
3.40; ARI, 0 more per 1000; 95% CI, 5 fewer to 17 more per
1000). We were unable to estimate the relative risk of major
reoperation, with no events occurring in the 2 studies reporting this
outcome.
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as very low owing to risk of bias, imprecision,
and indirectness of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel further judged that
the balance between benefits vs harms probably favors combina-
tion pharmacological and mechanical thromboprophylaxis over
pharmacological thromboprophylaxis alone. The panel judged the
costs associated with combined thromboprophylaxis to be
negligible based on very low certainty in the evidence of resource
requirements. Cost-effectiveness probably favors combined
pharmacological with mechanical thromboprophylaxis. The panel
agreed that the impact on health equity is likely to vary, depending
on the availability of mechanical prophylaxis methods. Combined
pharmacological and mechanical thromboprophylaxis would
probably be acceptable to stakeholders and probably feasible to
implement.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
panel made a conditional recommendation for using combination
thromboprophylaxis rather than pharmacological thromboprophy-
laxis alone for patients with cancer without VTE, as a result of a
balance of effects that probably favors the intervention. The
moderate desirable effects of the combined prophylaxis method
probably outweigh the trivial effect on harms. However, there is a
very low certainty in the evidence. The panel agreed that, in the
setting of patients with high VTE risk, they would particularly favor
the combined approach.
The panel agreed that further high-quality comparative data
would be of value to add more certainty to this recommendation.
Studies enabling identification of baseline risk would be valuable
to identify patients who are particularly likely to benefit from
combined prophylaxis strategies. Finally, more information about
the duration of compression (h/d) needed for VTE prevention
with IPCs would be valuable, as would be data about device
standardization.
Should LMWH, UFH, fondaparinux, VKAs, or DOACs be used for
thromboprophylaxis for patients with cancer undergoing a surgical
procedure?
LMWH vs UFH. SUMMARY OF THE EVIDENCE We identified 3
systematic reviews that addressed this question.51,129,131 From
these reviews, we identified 13 eligible RCTs that fulfilled our
inclusion criteria and measured outcomes relevant to this
context.177-189 Our systematic search of RCTs identified 3 additional
studies not included in the previous reviews that fulfilled the inclusion
criteria.190-192 All of these trials included only patients with active
cancer. The different types of surgeries included in these studies were
abdominal,178,179,182,183,185-187,191,193 pelvic,177,178,180,183,185,188,189,192
breast,177,189,192 thoracic,181,193 and neurosurgical.190 One trial did
not specify the type of surgery.186 Of these studies comparing LMWH
with UFH, 8 studies reported the effect onmortality,178,179,186,187,189-191,193
15 studies reported the effect on any PE,177-183,185-188,190-193 8 studies
reported the effect on any symptomatic DVT,177,178,180,183,187,190-192 9
studies reported the effect on major bleeding,177,178,180,181,183,186,187,190,193
and 4 studies reported on reoperation for bleeding.178,180,188,193Wedid
not find any studies evaluating the role of VKAs or DOACs in this setting.
The EtD framework is available at https://guidelines.ash.gradepro.org/
profile/bl0OZ3wdZCc.
BENEFITS. For patients with cancer undergoing a surgical pro-
cedure, LMWH compared with UFH probably results in little to
no difference in mortality, any DVT, and reoperation for bleeding,
and it results in little to no difference in any PE and any
symptomatic DVT. The panel judged these effects to be small (for
mortality: RR, 0.82; 95% CI, 0.63-1.07; ARR, 9 fewer per 1000;
95% CI, 19 fewer to 4 more per 1000; for any DVT: RR, 0.86;
95% CI, 0.69-1.06; ARR, 4 fewer per 1000; 95% CI, 8 fewer to 2
more per 1000; for reoperation for bleeding: RR, 0.93; 95% CI,
0.57-1.50; ARR, 4 fewer per 1000; 95% CI, 22 fewer to 26 more
per 1000; for any PE: RR, 0.52; 95% CI, 0.20-1.34; ARR, 6
fewer per 1000; 95% CI, 10 fewer to 4 more per 1000 using a
baseline risk of 1.3%194; for any symptomatic DVT: RR, 0.67;
95% CI, 0.27-1.69; ARR, 3 fewer per 1000; 95% CI, 7 fewer to 7
more per 1000).
HARMS AND BURDEN. For patients with cancer undergoing a surgical
procedure, LMWH compared with UFH results in little to no
difference in major bleeding, and the panel judged this effect to be
Recommendations 9 and 10
For patients with cancer undergoing a surgical procedure, the
ASH guideline panel suggests using LMWH or fondaparinux
for thromboprophylaxis rather than UFH (conditional recom-
mendation, low certainty in the evidence of effectsÅÅ◯◯). The
panel did not make a recommendation on the use of VKAs or
DOACs in this setting because there were no studies available.
Remarks: UFH is generally preferred over LMWH for patients
with cancer and severe renal impairment (defined as creatinine
clearance , 30 mL/min). If planning for extended thrombo-
prophylaxis (continuing pharmacological thromboprophylaxis at
home), the guideline panel suggests the use of LMWH (see
Recommendation 12).
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trivial (for major bleeding: RR, 1.01; 95%CI, 0.69-1.48; ARI, 1 more
per 1000; 95% CI, 17 fewer to 27 more per 1000).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as moderate owing to imprecision of the
estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel determined that
there is moderate certainty for a net health benefit from LMWH
(over UFH) for patients with cancer undergoing surgery. This was
supported by the fact that, given the relationship between desirable
and undesirable effects, there is probably no important uncertainty
or variability in how much patients value the outcomes. The panel
concluded that costs and savings are likely to be negligible and that,
based on the available evidence, the cost-effectiveness probably
favors LMWH.
The panel agreed that there is probably minimal impact on health
equity because, despite the variability in impact on health equity, for
short-term scenarios like hospitalized patients, the impact is less
likely (eg, in the United States, in-hospital drugs would typically be
covered by insurance plans or Medicare/Medicaid). The interven-
tion (LMWH) is probably acceptable for most patients and is
feasible given current practice.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
conditional recommendation for LMWH rather than UFH for
patients with cancer undergoing a surgical procedure is due to
moderate certainty in evidence, negligible costs and savings, and
cost-effectiveness that probably favors LMWH. The evidence was
graded as moderate certainty as a result of some imprecision in the
risk estimates for benefits and harms. The panel notes that UFH is
generally preferred over LMWH for patients with cancer with severe
renal impairment (creatinine clearance ,30 mL/min). The panel
noted that resource and economic parameters are likely to vary
between institutions and regions.
The panel agreed that, given the imprecision of the observed
effects, additional studies could increase the certainty in evidence.
Fondaparinux vs LMWH. SUMMARY OF THE EVIDENCE. We did not
identify any systematic review addressing this question. Our
systematic search of RCTs identified 3 that compared fondaparinux
with LMWH and fulfilled the inclusion criteria.195-197 These RCTs
included patients with cancer undergoing abdominal surgery,195
pelvic surgery,196 or surgery for esophageal cancer.197 None of the
identified studies reported on mortality, but all reported on VTE
(symptomatic and asymptomatic) and major bleeding. It was not
possible to abstract data on PE and symptomatic DVT; instead,
aggregate data on VTE rates were reviewed, and baseline risks for
any PE and symptomatic DVT were applied to calculate absolute
effects. The EtD framework is available at https://guidelines.ash.-
gradepro.org/profile/kC-K0WVaiPY.
BENEFITS. Compared with LMWH, fondaparinux may reduce PEs
and symptomatic DVTs slightly; the panel judged the effect to be
small (for PE: RR, 0.40; 95%CI, 0.14-1.12; ARR, 6 fewer per 1000;
95% CI, 9 fewer to 9 more per 1000 using a baseline risk of 1%194;
for symptomatic DVT: RR, 0.40; 95% CI, 0.14-1.12; ARR, 11 fewer
per 1000; 95% CI, 16 fewer to 2 more per 1000 using a baseline
risk of 1.9%).194
HARMS AND BURDEN. Compared with LMWH, fondaparinux may
increase major bleeding slightly; the panel judged the effect to be
small (for major bleeding: RR, 1.34; 95%CI, 0.81-2.22; ARI, 7 more
per 1000; 95% CI, 4 fewer to 27 more per 1000).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as low owing to the risk of bias and imprecision
of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel determined that
there is low certainty in the evidence for a net health benefit from
using fondaparinux (over LMWH) for patients with cancer un-
dergoing surgery and concluded that neither strategy is favored
over the other. The panel believed that the resource impact (costs
and savings) is likely to be negligible and that there is probably
no impact on health equity. No cost-effectiveness evidence was
identified.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
conditional recommendation (rather than strong) for using fonda-
parinux or LMWH is due to a balance that may favor fondaparinux;
however, the certainty in the evidence is low, and costs and/or
savings are likely negligible. If planning for extended thrombopro-
phylaxis (continuing pharmacological thromboprophylaxis at
home), the guideline recommends considering using LMWH to
facilitate logistics and transition of thromboprophylaxis to the
outpatient setting (see Recommendation 27). The guideline panel
considered further information on the comparative effectiveness
and safety of fondaparinux vs LMWH a research priority. The panel
agreed that further research on efficacy and cost-effectiveness is
needed.
Should preoperative thromboprophylaxis vs postoperative throm-
boprophylaxis be used for patients with cancer undergoing a
surgical procedure?
Preoperative thromboprophylaxis vs postoperative
thromboprophylaxis. SUMMARYOF THE EVIDENCE. The panel defined
preoperative thromboprophylaxis as a dose of LMWH or UFH
received 12 hours prior to the procedure (or the evening before)
and not a dose (eg, UFH, 5000 IU) that can be given at the time of
the surgery (or on the operating table). We did not identify any
systematic review addressing this question. Our systematic search
Recommendation 11
For patients with cancer undergoing a surgical procedure, the
ASH guideline panel suggests using postoperative thrombo-
prophylaxis over preoperative thromboprophylaxis (conditional
recommendation, low certainty in the evidence of effects
ÅÅ◯◯).
Remarks: The panel defined preoperative thromboprophylaxis
as a dose of LMWH or UFH given 12 hours (or the evening
before) prior to the procedure and not the dose given at the
time of the surgery (or on the operating table). The panel did
not recognize a large advantage to preoperative prophylaxis
and took a precautionary approach because of the bleeding
and logistical considerations with neuraxial anesthesia. Pa-
tients with cancer already hospitalized prior to the surgery are
suggested to receive thromboprophylaxis as per Recommen-
dations 1 and 2.
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of RCTs identified 1 that fulfilled the inclusion criteria.198 This RCT
included patients undergoing major laparotomy in the peritoneal
and/or retroperitoneal space and/or pelvis. It compared the effect of
an ultra-LMWH starting 86 1 hour postoperation with prophylactic
LMWH starting before surgery, with the first postoperative injection
starting 12 6 1 hour postoperation. Outcomes included mortality,
PE, symptomatic DVT, and major bleeding. It was noted that many
studies assessing thromboprophylaxis in this patient population
initiated thromboprophylaxis preoperatively,201-203 whereas others
started it during the postoperative period.202,203 The EtD frame-
work is available at https://guidelines.ash.gradepro.org/profile/
boP4bq0N0s8.
BENEFITS. Preoperative thromboprophylaxis compared with postop-
erative thromboprophylaxis may reduce mortality, any PE, and any
symptomatic DVT but the evidence is very uncertain. The panel
judged these effects to be small (for mortality the RR was 0.74, 95%
CI 0.50 to 1.09; ARR 7 fewer per 1000, 95% CI from 13 more to 2
more per 1000; for any PE, the RR was 0.20, 95% CI 0.01 to 4.16;
ARR, 10 fewer per 1000, 95% CI from 13 fewer to 41 more per
1000 using a baseline risk of 1.3%204; for any symptomatic DVT the
RR was 0.86, 95% CI 0.62 to 1.19; ARR 1 fewer per 1000, 95% CI
from 2 fewer to 1 more per 1000 using a baseline risk of 0.4%).204
HARMS AND BURDEN. Preoperative thromboprophylaxis compared
with postoperative thromboprophylaxis increases major bleeding,
but the evidence is very uncertain. The panel judged these effects to
be small (for major bleeding: RR, 1.55; 95% CI, 1.14-2.12; ARI, 16
more per 1000: 95% CI, 4-32 more per 1000).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as very low because of indirectness and imprecision
of the estimates. With regard to indirectness, in the single identified
RCT, the drug used for postoperative administration was ultra-
LMWH, which does not reflect the current practice. Also, both arms
of the trial had the anticoagulant administered for 7 to 10 days,
including the group that started enoxaparin preoperatively. Addi-
tionally, because the experimental arm involved a different drug and
a different timing compared with the control arm, it is challenging to
interpret the results.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel determined that
there is very low certainty in the evidence for a net health benefit of
preoperative thromboprophylaxis vs postoperative thromboprophy-
laxis and concluded that the balance probably favors immediate
postoperative thromboprophylaxis. The panel further discussed that
preoperative prophylaxis seemed to only modestly decrease the risk
of VTE, but it also seemed to increase the risk of bleeding. The
recommendation is conditional because of low-quality evidence.
The panel believed that the resource use (cost and savings) may be
negligible but noted that preoperative administration might require
preoperative admission in certain settings, resulting in a cost
increase.
The panel agreed that there is probably no impact on health equity
because, despite the variability in impact on health equity, for short-
term scenarios like hospitalized patients, the impact is less likely. No
cost-effectiveness evidence was identified. The panel noted that
acceptability and feasibility may vary between settings, particularly
given that, in some settings, preoperative administration of pro-
phylaxis may require preoperative admission that may be difficult to
organize and that issues concerning neuraxial anesthesia must also
be considered.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS.
The conditional recommendation for using postoperative, rather
than preoperative, thromboprophylaxis is due to a balance of
effects that probably favors postoperative thromboprophylaxis,
because of the small potential reduction in VTE and mortality but,
more likely, an increase in the risk of bleeding. The panel did not
recognize a large advantage to preoperative prophylaxis and took
a precautionary approach because of bleeding and logistical
considerations with neuraxial anesthesia, which were based on
very low certainty in the evidence. The panel strongly recom-
mends future research into the optimal timing of perioperative
anticoagulation.
Should extended thromboprophylaxis (continuing pharmacological
thromboprophylaxis at home) vs limited thromboprophylaxis (7-10
days; discontinuing thromboprophylaxis at the time of discharge)
be used for patients with cancer who have undergone a surgical
procedure?
Extended (continue at home) vs limited (7-10 days;
discontinue at the time of discharge). SUMMARY OF THE
EVIDENCE. We identified 4 systematic reviews addressing this
question.205-208 We identified 5 studies that fulfilled our inclusion
criteria and measured outcomes relevant to this context.199-201,203,209
Our systematic search for RCTs identified 1 additional study that
fulfilled the inclusion criteria.202 Four studies included only patients
with cancer,199,201-203 whereas in the remaining 2 studies, the
majority of the patients had cancer.200,209 All trials reported on
abdominal cancer, and 2 also included pelvic cancer.199,203 All
studies included patients undergoing abdominal/pelvic surgery. Five
studies compared LMWH administered for 4 weeks postoperatively
with LMWH administered for 1 week postoperatively.199-201,203,209
One study compared the use of extended thromboprophylaxis with
LMWH vs discontinuation of LMWH upon hospital discharge.202
Two studies reported the use of compression stockings in both study
arms for 1 week.200,209 All 6 studies reported on mortality.199-203,209
Five studies reported on PEs and symptomatic DVTs.199-201,203,209
Four studies reported data on asymptomatic DVTs.199-201,203 Five
studies reported data on major bleeding,199-203 1 study reported on
HIT,200 and 1 study reported on rates of reoperation for bleeding.201
Recommendation 12
For patients with cancer who had undergone a major abdominal/
pelvic surgical procedure, the ASH guideline panel suggests
continuing pharmacological thromboprophylaxis postdischarge
rather than discontinuing at the time of hospital discharge (con-
ditional recommendation, very low certainty in the evidence of
effects Å◯◯◯).
Remarks: Although we searched for evidence for all surgical
procedures, we only identified evidence to assess the benefits
and harms of extended thromboprophylaxis for patients un-
dergoing major abdominal/pelvic surgery; this recommendation
should not be extended to other surgical procedures (see
Recommendations 9 and 10). Patients should be provided
comprehensive anticoagulation education, including self-injection
technique, during hospitalization to facilitate continuation of
thromboprophylaxis after discharge.
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The EtD framework is available at https://guidelines.ash.grade-
pro.org/profile/2GovinJ5W_0.
BENEFITS. Extended thromboprophylaxis (up to 4 weeks) compared
with limited thromboprophylaxis (7-10 days; discontinuing at the
time of hospital discharge) may reduce PEs and symptomatic
DVTs, but the evidence is very uncertain. Extended thrombopro-
phylaxis reduces asymptomatic DVTs slightly. The panel judged
these benefits to be small (for PE: RR, 0.18; 95% CI, 0.02-1.46;
ARR, 14 fewer per 1000; 95% CI, 17 fewer to 8 more per 1000
using a baseline risk of 1.7%210; for symptomatic DVT: RR, 0.67;
95% CI, 0.11-4.06; ARR, 10 fewer per 1000; 95% CI, 26 fewer
to 89 more per 1000 using a baseline risk of 2.9%210; for
asymptomatic DVT: RR, 0.50; 95% CI, 0.33-0.74; ARR, 14 fewer
per 1000; 95% CI, 8-19 fewer per 1000 using a baseline risk of
2.9%).210
HARMS AND BURDEN. Extended thromboprophylaxis (up to 4 weeks)
compared with limited thromboprophylaxis (7-10 days; discon-
tinuing at the time of hospital discharge) may result in little to no
effect on major bleeding and reoperation for bleeding, but the
evidence is very uncertain. It may increase mortality slightly, and
the panel judged these effects to be small (for major bleeding:
RR, 0.83; 95% CI, 0.29-2.35; ARR, 2 fewer per 1000; 95% CI, 7
fewer to 14 more per 1000; for reoperation for bleeding: RR,
0.50; 95% CI, 0.05-5.48; ARR, 9 fewer per 1000; 95% CI, 17
fewer to 79 more per 1000; for mortality: RR, 1.14; 95% CI,
0.73-1.78; ARI, 6 more per 1000; 95% CI, 12 fewer to 35 more
per 1000). We were unable to estimate the relative risk of HIT,
because no events occurred in the study reporting this
outcome.200
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as very low because of the risk of bias and
imprecision of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel determined that,
although there is very-low-certainty evidence of a net health benefit
from extending thromboprophylaxis rather than discontinuing at the
time of hospital discharge, the balance probably favors extended
thromboprophylaxis. The panel believed that the resources (cost
and savings) were moderate and that cost-effectiveness probably
favors the intervention.
The panel noted that extended prophylaxis could cause inequity
because of concerns about cost and the ability to self-inject. Some
patients might find the intervention unacceptable with respect to
having to continue with injections at home. For some patients, the
intervention might not be feasible (eg, if they are transferred to home
or long-term care without support for injections).
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
conditional recommendation for extending thromboprophylaxis,
rather than discontinuing at the time of hospital discharge, is due
to a balance between desirable and undesirable effects that
probably favor continuing pharmacological thromboprophylaxis
after discharge based on very-low-quality evidence and possible
favorable cost-effectiveness.
The panel noted that, in case of a shorter hospital stay, the current
recommendation would likely not differ, because the risk of VTE
persists for a long period after surgery. The panel agreed that more
data are required because most of the evidence comes from
abdominal or pelvic surgery.
Primary prophylaxis for ambulatory patients with
cancer receiving systemic therapy
Should parenteral thromboprophylaxis vs no thromboprophylaxis be
used for ambulatory patients with cancer receiving systemic therapy?
Parenteral thromboprophylaxis vs no thromboprophylaxis.
SUMMARY OF THE EVIDENCE. We identified 13 systematic reviews
addressing this question.211-222 From these reviews, we identified
17 eligible RCTs that fulfilled our inclusion criteria and measured
outcomes relevant to this clinical setting.223-238 One systematic
review evaluated the efficacy and safety of LMWH prophylaxis for
patients receiving chemotherapy for lung cancer.222 This system-
atic review included 5 Chinese studies that we could not retrieve as
full texts.239-243 The panel decided to base the meta-analysis on
individual participant data. Of the 17 eligible RCTs, we included 12
RCTs for which we had access to their individual participant data in
the meta-analysis.223-225,228-234,237,238 One study used UFH as the
intervention,229 and another used ultra-LMWH223; the rest used
LMWH.224,225,228,230-234,237,238 We did not identify any study using
fondaparinux as the intervention. Cancers included in these studies
were abdominal,223,228,233,234,237,238 thoracic,223-225,228-231,233,234
breast,225,228,233 pelvic,223,228,233,234 skin,228 and neurological.232
The result of the individual participant data meta-analysis was not
significantly different from the results from the group-level data
systematic review.211 The EtD framework is available at https://
guidelines.ash.gradepro.org/profile/5Fxh8ECm1hk.
BENEFITS. Parenteral thromboprophylaxis compared with no throm-
boprophylaxis probably reduces mortality slightly, reduces any VTE
and symptomatic VTEs, results in little to no difference in
asymptomatic VTEs, and reduces PEs slightly. Parenteral thrombo-
prophylaxis results in a large reduction in any symptomatic DVT for
patients at high risk for thrombosis, reduces any symptomatic DVT
for patients at intermediate risk for thrombosis, and reduces any
symptomatic DVT slightly for patients at low risk for thrombosis. The
panel judged the benefits to be small for patients at low risk for
Recommendation 13
For ambulatory patients with cancer at low risk for thrombosis
receiving systemic therapy, the ASH guideline panel recom-
mends no thromboprophylaxis over parenteral thromboprophy-
laxis (strong recommendation, moderate certainty in the evidence
of effects ÅÅÅ◯). For ambulatory patients with cancer at in-
termediate risk for thrombosis receiving systemic therapy, the
ASH guideline panel suggests no prophylaxis over parenteral
prophylaxis (conditional recommendation, moderate certainty in
the evidence of effects ÅÅÅ◯). For ambulatory patients with
cancer at high risk for thrombosis receiving systemic therapy, the
ASH guideline panel suggests parenteral thromboprophylaxis
(LMWH) over no thromboprophylaxis (conditional recommenda-
tion, moderate certainty in the evidence of effects ÅÅÅ◯).
Remarks: Classification of patients as being low-, intermediate-,
or high-risk for VTE should be based on a validated risk-assess-
ment tool (ie, Khorana score) complemented by clinical judgment
and experience. The panel noted that, even for patients at high
risk for thrombosis, thromboprophylaxis should be used with
caution in those with a high risk for bleeding.
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thrombosis, moderate for patients at intermediate risk for thrombosis,
and large for patients at high risk for thrombosis. For mortality: RR,
0.97; 95% CI, 0.90-1.03; ARR, 15 fewer per 1000; 95% CI, 50
fewer to 15 more per 1000. For any VTE: RR, 0.57, 95% CI, 0.46-
0.71; ARR, 30 fewer per 1000; 95% CI, 20-38 fewer per 1000. For
symptomatic VTE: RR, 0.53; 95% CI, 0.40-0.70; ARR, 27 fewer per
1000; 95% CI, 18-35 fewer per 1000. For asymptomatic VTE: RR,
0.63; 95% CI, 0.39-1.02; ARR 5 fewer per 1000; 95% CI, 0-8 fewer
per 1000. For PE: RR, 0.53; 95% CI, 0.39-0.73; ARR, 13 fewer per
1000; 95% CI, 8-18 fewer per 1000. For any symptomatic DVT: RR,
0.55; 95% CI, 0.38-0.80; ARR, 16 fewer per 1000; 95% CI, 7-21
fewer per 1000 using a baseline risk of 3.5%; ARR, 45 fewer per
1000; 95% CI, 20-62 fewer per 1000 using a baseline risk of 10%244;
ARR, 86 fewer per 1000; 95% CI, 38-119 fewer per 1000 using a
baseline risk of 19.2%.244 Parenteral thromboprophylaxis probably
results in little to no difference in quality-of-life impairment.231,233
HARMS AND BURDEN. Parenteral thromboprophylaxis compared with
no thromboprophylaxis likely results in little to no difference in major
bleeding, and the panel judged the effect to be trivial (RR, 1.16;
95% CI, 0.85-1.59; ARI, 3 more per 1000; 95% CI, 3 fewer to 11
more per 1000). With input from the patient representative, the panel
agreed that the burden of treatment and additional side effects, such
as local hematomas in the context of cancer treatment, may represent
a small or unimportant burden. However, qualitative research
demonstrates that the burden may vary and is likely to be higher
between patients who are receiving anticoagulation for treatment
and those who are receiving anticoagulation for prophylaxis.41
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as moderate for patients at immediate risk for
thrombosis and high for patients at high risk for thrombosis because
of risk of bias and imprecision of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel determined that for
patients with cancer receiving systemic cancer therapy at low risk for
thrombosis, there is moderate certainty in the evidence that neither
parenteral thromboprophylaxis nor thromboprophylaxis is favored; thus,
they recommended against thromboprophylaxis. For patients at
intermediate risk for thrombosis, there is moderate certainty in the
evidence for a net health benefit from parenteral thromboprophylaxis,
and the panel agreed that the balance probably favors parenteral
thromboprophylaxis. For patients at high risk for thrombosis, there is
high-certainty evidence favoring parenteral thromboprophylaxis.
The panel thought that the resources (cost and savings) were
moderate and that cost-effectiveness probably favors the intervention
for patients at high risk for thrombosis. The cost of managing VTE and
anticoagulation will vary by health system, region, and payer setting.
Costs in the United States are greater than in many other developed
countries, and out-of-pocket expenses continue to increase.
The panel agreed that equity would probably be reduced with the
use of parenteral thromboprophylaxis because there are groups of
patients who would not have access to expensive outpatient
medications, and drug approval for this indication will differ. The
panel also agreed that acceptability will vary. From the patients’
perspective, it may depend on baseline risk for patients, being more
acceptable for patients with a higher risk for thrombosis. From the
health care professionals’ perspective, it may also depend on
baseline risk of thrombosis. Some clinicians and patients may be
concerned about cost-effectiveness and the burden of prescribing
when LMWH is not routinely covered by insurance plans.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS.
Overall, the panel concluded that primary prophylaxis with
LMWH for ambulatory patients receiving cancer chemotherapy
reduces the risk of VTE with a minor increase in the risk of
bleeding and with no impact on overall survival. The panel made
3 different recommendations, depending on the baseline risk of
thrombosis (eg, Khorana score).245 For patients at low risk for
thrombosis, the panel made a strong recommendation against
the use of routine parenteral thromboprophylaxis. For patients
at intermediate risk for thrombosis, the panel made a condi-
tional recommendation for the use of routine parenteral
thromboprophylaxis. For patients at high risk for thrombosis,
the panel made a conditional recommendation for the use of
parenteral thromboprophylaxis.
Research priorities highlighted by the panel include determining
the benefits and harms of VTE prophylaxis for patients at
intermediate risk for thrombosis and determining the benefits
and harms by tumor type. The panel believed that development of
additional validated decision aids and educational material
(awareness of thrombosis risk and symptoms) could be helpful.
The panel agreed that additional cost-effectiveness data may be
required in different health care settings and for different risk
groups, particularly high-risk patients, to address the cost-
effectiveness of this intervention.
Should oral thromboprophylaxis vs no thromboprophylaxis be used
for ambulatory patients with cancer receiving systemic therapy?
Recommendations 14 and 15
For ambulatory patients with cancer receiving systemic therapy,
the ASH guideline panel recommends no thromboprophylaxis
over oral thromboprophylaxis with VKAs (strong recommenda-
tion, very low certainty in the evidence of benefitsÅ◯◯◯ but high
certainty about the harms ÅÅÅÅ). For ambulatory patients with
cancer at low risk for thrombosis receiving systemic therapy, the
ASH guideline panel suggests no thromboprophylaxis over oral
thromboprophylaxis with a DOAC (apixaban or rivaroxaban)
(conditional recommendation, moderate certainty in the evi-
dence of effectsÅÅÅ◯). For ambulatory patients with cancer at
intermediate risk for thrombosis receiving systemic therapy, the
ASH guideline panel suggests thromboprophylaxis with a DOAC
(apixaban or rivaroxaban) or no thromboprophylaxis (conditional
recommendation, moderate certainty in the evidence of effects
ÅÅÅ◯). For ambulatory patients with cancer at high risk for
thrombosis receiving systemic therapy, the ASH guideline panel
suggests thromboprophylaxis with a DOAC (apixaban or rivar-
oxaban) over no thromboprophylaxis (conditional recommenda-
tion, moderate certainty in the evidence of effects ÅÅÅ◯).
Remarks: Classification of patients as being at low, in-
termediate, or high risk for VTE should be based on a validated
risk assessment tool (ie, Khorana score) complemented by
clinical judgment and experience. The panel noted that, even
for patients at high risk for thrombosis, thromboprophylaxis
should be used with caution for those at high risk for bleeding.
The direct factor Xa inhibitors apixaban and rivaroxaban are the
only DOACs that were evaluated for the primary prophylaxis for
ambulatory patients with cancer receiving chemotherapy.
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VKA thromboprophylaxis vs no thromboprophylaxis.
SUMMARY OF THE EVIDENCE. We identified 4 systematic reviews that
addressed, in part, this question.214,217,246,247 From these reviews,
we identified 6 eligible RCTs that fulfilled our inclusion criteria and
measured outcomes relevant to this context among ambulatory
patients with cancer receiving systemic therapy.248-253 Five trials
reported on the effect of VKA vs no prophylaxis on mortality,248-253 1
trial report on PEs and symptomatic DVTs,249 and 5 studies reported
on major bleeding.248-250,252,253 The different types of cancers
included in these studies were thoracic,248,250-253 abdominal,252
breast,249 urological,254 and head and neck.252 The EtD framework
is available at https://guidelines.ash.gradepro.org/profile/rvJIcDQvhhU.
BENEFITS. For ambulatory patients with cancer receiving systemic
therapy, VKA thromboprophylaxis compared with no thrombopro-
phylaxis probably reduces mortality, may have little to no effect on
PEs, and may reduce symptomatic DVTs; however, the evidence is
very uncertain. The panel judged these desirable effects as
moderate across groups with a low or intermediate risk for DVT
and as large for the high-risk group (for mortality: RR, 0.95; 95% CI,
0.87-1.03; ARR, 29 fewer per 1000; 95%CI, 17 more to 75 fewer
per 1000; for PE: RR, 1.05; 95% CI, 0.07-16.58; ARR, 0 fewer
per 1000, 95% CI, 6 fewer to 98 more per 1000; for symptomatic
DVT: RR, 0.08; 95% CI, 0.0046-1.42; ARR, 35 fewer per 1000
using a baseline risk of 3.8%; ARR, 92 fewer per 1000 using a
baseline risk of 10%244; ARR, 177 fewer per 1000 using a baseline
risk of 19.2%).244
HARMS AND BURDEN. VKA thromboprophylaxis compared with no
thromboprophylaxis increases major bleeding, and the panel judged
the harms and burden to be large (RR, 2.89; 95% CI, 2.07-4.04;
ARI, 106 more per 1000; 95% CI, 60-170 more per 1000).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in the evidence for
the benefits was judged as very low because of indirectness and
imprecision of the estimates. However, the certainty in the evidence
for the harm from bleeding was judged as high.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel concluded that
there is very-low-certainty evidence of a net health benefit from VKA
thromboprophylaxis and high certainty about the harms (with the
risk of major bleeding outweighing the benefits of DVT reduction
across risk groups) and concluded that the balance of effects
probably favors no thromboprophylaxis.
Although the panel agreed that the costs of VKAs are very low, VKA
monitoring and major bleeding are costly. Given the lack of cost-
effectiveness data, the panel concluded that the cost-effectiveness
favors no thromboprophylaxis over thromboprophylaxis with VKA.
The panel agreed that equity would probably be reduced with the
use of VKA thromboprophylaxis, because there are groups of
patients who would face difficulty with ensuring adequate access
to VKA monitoring. Nevertheless, the panel also agreed that,
although some patients and caregivers might find the logistics of
VKA monitoring unacceptable, the intervention would probably be
acceptable to key stakeholders.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS.
The strong recommendation for no thromboprophylaxis over thrombo-
prophylaxis with a VKA for ambulatory patients with cancer without VTE
and receiving systemic therapy is due to the low certainty in the
evidence of the benefits and the high certainty about the harms,
moderate costs, and cost-effectiveness, such that the balance of
effects probably favors no thromboprophylaxis. The GRADE
approach includes situations in which strong recommendations
are warranted, despite very low certainty in the evidence of the
effects, including situations in which high certainty about the harms
of the intervention outweighs the potential benefit.255 The panel
agreed that this question is not a research priority, given the
potential alternative interventions.
DOAC thromboprophylaxis vs no thromboprophylaxis.
SUMMARY OF THE EVIDENCE. We identified 5 systematic reviews that
addressed, in part, this question.214,217,246,247,256 From these
reviews, we identified 3 eligible RCTs that fulfilled our inclusion
criteria and measured outcomes relevant to this context.257-259 The
most common types of cancer included gynecologic, lymphoma,
lung, and pancreatic. Patients in the AVERT and CASSINI trials had
a moderate to high risk for VTE (Khorana score $ 2).257,258 Apixaban
was the intervention in 2 of the studies,257,259 whereas rivaroxaban was
used in the third study.258 All 3 studies assessed the efficacy of
DOACs compared with no prophylaxis or placebo on mortality,
PEs, symptomatic DVTs, and major bleeding. The EtD framework
for populations with low risk for thrombosis is available at https://
guidelines.ash.gradepro.org/profile/rPFlhvr3GUE. The EtD frame-
work for populations with intermediate risk for thrombosis is available
at https://guidelines.ash.gradepro.org/profile/7D9gHSZbMnE. The
EtD framework for populations with high risk for thrombosis is
available https://guidelines.ash.gradepro.org/profile/qmBqSB7Txqg.
BENEFITS. For ambulatory patients with cancer receiving systemic
therapy, thromboprophylaxis with a DOAC (apixaban or rivarox-
aban) compared with no thromboprophylaxis probably reduces
mortality, PEs, and symptomatic DVTs. The panel judged desirable
effects as small for patients with a low risk for DVT and as moderate
for patients with a moderate or high risk for DVT (for mortality: RR,
0.94; 95% CI, 0.64-1.38; ARR, 11 fewer per 1000; 95% CI, 67
fewer to 70 more per 1000; for PE: RR, 048; 95% CI, 0.24-0.98;
ARR, 24 fewer per 1000; 95% CI, 1-34 fewer per 1000; for
symptomatic DVT: RR, 0.61; 95% CI, 0.31-1.21; ARR, 7 fewer per
1000; 95% CI, 12 fewer to 4 more per 1000 using a baseline risk of
1.7%260; ARR, 20 fewer per 1000; 95% CI, 34 fewer to 10 more per
1000 using a baseline risk of 5%244; ARR, 37 fewer per 1000; 95%CI,
66 fewer to 20 more per 1000 using a baseline risk of 9.5%).244
HARMS AND BURDEN. Thromboprophylaxis with a DOAC compared
with no thromboprophylaxis probably increases major bleeding
slightly, and the panel judged this effect as small (RR, 1.65; 95%CI,
0.72-3.80; ARI, 12 more per 1000; 95% CI, 50 more to 5 fewer per
1000 using a baseline risk of 1.8%).244
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as moderate because of imprecision of the
estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel determined that
there is moderate certainty in the evidence that, in the low-risk
group, there is not a net health benefit from DOAC thrombopro-
phylaxis and concluded that the balance of effects does not favor
thromboprophylaxis with a DOAC or no thromboprophylaxis. In the
case of the intermediate-risk group, the panel concluded that the
balance probably favors the use of DOACs, and it favors the use of
DOACs in the high-risk group.
The panel agreed that costs will vary depending on the risk of
thrombosis and that the intervention is likely to be more cost-
effective if applied in the high-risk group. The panel agreed that
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equity would probably be reduced with the use of DOAC
thromboprophylaxis, because there are groups of patients who
would not have the financial resources to cover the medications.
Furthermore, drug availability and approval for this indication will
likely differ across settings. The panel also agreed that acceptability
will vary. In the case of patients, it may depend on the baseline risk
for VTE, being more acceptable for patients with a higher risk for
thrombosis. Some patients might also be concerned about not
receiving any intervention. In the case of health care professionals, it
may also depend on the baseline risk of VTE.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS.
Overall, the panel concluded that primary prophylaxis with a DOAC
for ambulatory patients receiving systemic therapy reduces the risk
of VTE with a minor increase in the risk of bleeding. The panel made
3 recommendations, depending on the baseline risk of thrombosis
(ie, Khorana score).245 For patients at low risk for thrombosis, the
panel made a conditional recommendation (rather than strong)
against the use of DOACs for ambulatory patients with cancer and
without VTEs who are receiving systemic therapy. For patients at
intermediate risk for thrombosis, the panel made a conditional recom-
mendation (rather than strong) for either DOAC or nonprophylaxis. For
patients at high risk for thrombosis, the panel made a conditional
recommendation (rather than strong) for the use of DOACs.
Classification of patients as having a low, moderate, or high risk for
VTE should be based on a validated score (ie, Khorana score)245
complemented by clinical judgment and experience. For patients at
high risk for thrombosis, thromboprophylaxis should be used with
caution for those with a high risk for bleeding. The panel believed
that additional trials comparing thromboprophylaxis with LMWH
vs DOACs are required to help inform decisions for this patient
population.
Should low-dose ASA thromboprophylaxis vs LMWH vs fixed-dose
VKA thromboprophylaxis be used for ambulatory patients withmultiple
myeloma receiving lenalidomide-, thalidomide-, or pomalidomide-
based regimens?
Low-dose ASA thromboprophylaxis vs fixed-dose
VKA. SUMMARY OF THE EVIDENCE. We identified 1 systematic
review that addressed this question.261 From this review, we
identified 1 eligible RCT that fulfilled our inclusion criteria and
measured outcomes relevant to this context.262 The trial assessed
the effect of low-dose ASA vs fixed-dose VKA (1.25 mg
daily) on mortality, PEs, symptomatic DVTs, and major bleeding at
6 months for ambulatory patients with multiple myeloma receiving
lenalidomide- or thalidomide-based regimens. The EtD frame-
work is available at https://guidelines.ash.gradepro.org/profile/
Ir8bZ95T8vw.
BENEFITS. Low-dose ASA thromboprophylaxis compared with fixed-
dose VKA thromboprophylaxis probably results in little to no
difference in mortality and any PEs and may reduce any
symptomatic DVTs slightly. The panel judged the desirable
effects as small (for mortality: RR, 3.00; 95% CI, 0.12-73.24,
with only 1 reported event occurring in the low-dose ASA
thromboprophylaxis group [n 5 220] and no events occurring in
the fixed-dose VKA thromboprophylaxis group [n 5 220]; for PE:
RR, 1.00; 95% CI, 0.25-3.95; ARR, 0 fewer per 1000; 95% CI,
14 fewer to 54 more per 1000; for any symptomatic DVT: RR,
0.57; 95% CI, 0.24-1.33; ARR, 27 fewer per 1000; 95% CI, 48
fewer to 21 more per 1000).
HARMS AND BURDEN. Low-dose ASA thromboprophylaxis compared
with fixed-dose VKA thromboprophylaxis may slightly increase the
risk of major bleeding. The panel judged the undesirable effects as
small (for major bleeding: RR, 7.00; 95% CI, 0.36-134.72; ARI, 14
more per 1000; 95% CI, 1 fewer to 308 more per 1000 using a
baseline risk of 0.2%).262
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in the evidence for
the benefits was judged as low because of imprecision of the
estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel determined
that there is low-certainty evidence of a net health benefit from
low-dose ASA over fixed-dose VKA thromboprophylaxis and
concluded that the balance of effects does not favor either. The
panel agreed that the anticipated benefits are similar to the
harms, because the bleeding was considered to be of greater
importance and possibly more frequent than the prevented
DVTs; overall, this led to a balanced assessment of the health
benefits and harms.
The panel was uncertain about the magnitude of resource
requirements (and associated costs), and no study about cost-
effectiveness was available. There is probably no impact on equity
with either intervention, with monitoring probably already taking
place through health care visits because of myeloma treatment.
VKA is less acceptable to patients and clinicians because of the
associated burden, including monitoring.
Low-dose ASA vs LMWH. SUMMARY OF THE EVIDENCE. We
identified a systematic review that addressed this question.261
From this review, we identified 2 eligible RCTs that fulfilled
our inclusion criteria and measured outcomes relevant to this
context.262,263 The trials assessed the effect of low-dose ASA vs
LMWH on mortality, PEs, symptomatic DVTs, and major bleeding at
6 months for ambulatory patients with multiple myeloma and without
VTE receiving lenalidomide- or thalidomide-based regimens. The
EtD framework is available at https://guidelines.ash.gradepro.org/
profile/IPXqGJq4cY8.
Recommendations 16 and 17
For multiple myeloma patients receiving lenalidomide-, thalid-
omide-, or pomalidomide-based regimens, the ASH guideline
panel suggests using low-dose ASA, fixed low-dose VKA, or
LMWH (conditional recommendation, low certainty in the evi-
dence of effects ÅÅ◯◯).
Remarks: Treatment with ASA, low-dose VKA, or LMWH de-
pends on patient preferences and the cost-effectiveness, which
may vary across settings. When cost and feasibility are less of a
concern, LMWH may be the better choice. Because of greater
efficacy, LMWH should be considered for patients at higher risk
for VTE; however, the panel notes that subcutaneous adminis-
tration of LMWH over a long period of time may not be ac-
ceptable to some patients. An increased risk for bleeding is likely
in patients on ASA who are also receiving steroids. Data on
thromboprophylaxis for patients receiving pomalidomide-based
regimen are lacking, but the panel believed that the benefits and
harms of thromboprophylaxis were likely similar to those in pa-
tients receiving thalidomide- or lenalidomide-based regimens.
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BENEFITS. Low-dose ASA vs LMWH thromboprophylaxis may result
in little to no difference in mortality, PEs, and any symptomatic DVTs.
The panel judged the desirable effects as trivial (for mortality: RR,
1.00; 95% CI, 0.06-15.81; ARR, 0 fewer per 1000; 95% CI,
2 fewer to 38 more per 1000; for PE: RR, 7.71; 95% CI, 0.97-
61.44; with only 7 reported events occurring in the low-dose ASA
thromboprophylaxis group [n 5 396] and 0 events occurring in the
LMWH thromboprophylaxis group [n 5 385]; for any symptomatic
DVT: RR, 1.23; 95% CI, 0.49-3.08; ARI, 5 more per 1000; 95% CI,
11 fewer to 43 more).
HARMS AND BURDEN. Low-dose ASA thromboprophylaxis com-
pared with LMWH thromboprophylaxis may increase major
bleeding slightly. The panel judged the undesirable effects as trivial
(major bleeding: RR, 6.97; 95% CI, 0.36-134.11; ARI, 8 more
per 1000; 95% CI, 1 fewer to 173 more using a baseline risk of
0.1%).262,263
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in the evidence for
the benefits was judged as low because of imprecision of the
estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel determined that
there is low-certainty evidence of a net health harm from low-dose
ASA over LMWH thromboprophylaxis and concluded that the
balance of effects probably favors LMWH.
The panel judged as moderate the magnitude of resource require-
ments (and associated costs) and that the cost-effectiveness probably
favors low-dose ASA thromboprophylaxis. Given the burden of
LMWH administered over a long period of time, low-dose ASA is
likely more acceptable for patients and is probably more accept-
able for payers. Feasibility is likely to be reduced with LMWH, but
low-dose ASA is feasible to implement.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
conditional recommendation for low-dose ASA thromboprophy-
laxis or fixed-dose VKA thromboprophylaxis for ambulatory patients
with multiple myeloma receiving lenalidomide-, thalidomide-, or
pomalidomide-based regimens is due to a balance of effects
that does not favor either in the context of low-certainty evidence of
the effects, uncertain costs, and no information about cost-
effectiveness. Increased bleeding risk is likely for patients on ASA
who are also receiving steroids.
The conditional recommendation for low-dose ASA thrombopro-
phylaxis or LMWH thromboprophylaxis for ambulatory patients with
multiplemyeloma receiving lenalidomide-, thalidomide-, or pomalidomide-
based regimens is due to a balance of effects that probably favors
LMWH, in the context of low-certainty evidence of the effects, and
cost-effectiveness that probably favors low-dose ASA.
The panel agreed that RCTs that evaluate the effect of DOACs, as
well as decision aids, are needed to answer this question. Further
evaluation of risk factors for VTE in this population is needed, with
prospective trials assessing thromboprophylaxis based on validated
risk models for VTE.
Primary prophylaxis for patients with cancer with
a CVC
Should parenteral thromboprophylaxis vs oral thromboprophylaxis
vs no thromboprophylaxis be used for patients with cancer with a
CVC?
Parenteral thromboprophylaxis vs no thromboprophylaxis.
SUMMARY OF THE EVIDENCE. We identified 6 systematic reviews
addressing this question.264-269 From these reviews, we identified
6 eligible RCTs that fulfilled our inclusion criteria and measured
outcomes relevant to this question.270-275 Our systematic search of
RCTs did not identify any additional studies. Five trials reported on the
effect of LMWH compared with no prophylaxis on mortality,270-273,275
6 trials reported on symptomatic catheter-related thrombosis,270-275
and 4 trials reported on major bleeding.270,271,274,275 All studies
reported primarily on solid tumors, with the exception of the study by
Niers et al, which focused on hematological tumors.274 The timing of
LMWH administration ranged from 2 hours prior to CVC insertion to
90 days after, CVC removal, or thrombosis diagnosis, whichever
occurred first. In most studies, the CVC was inserted in the
subclavian vein. The EtD framework is available at https://guide-
lines.ash.gradepro.org/profile/XuHZ1KtjScI.
BENEFITS. LMWH thromboprophylaxis compared with no thrombo-
prophylaxis may reduce mortality and symptomatic catheter-related
thrombosis, but the evidence is very uncertain. The panel judged
desirable effects as moderate (for mortality: RR, 0.82; 95% CI,
0.53-1.26; ARR, 14 fewer per 1000; 95% CI, 36 fewer to 20 more
per 1000; for symptomatic catheter-related thrombosis: RR, 0.48;
95% CI, 0.27-0.86; ARR, 14 fewer per 1000; 95% CI, 4-20 fewer
using a baseline risk of 2.7%).276
HARMS AND BURDEN. LMWH compared with no thromboprophylaxis
may have little to no effect on major bleeding, but the evidence is
very uncertain. The panel judged undesirable effects as trivial (for
major bleeding: RR, 0.49; 95% CI, 0.03-7.84; ARR, 1 fewer per
1000; 95% CI, 2 fewer to 16 more per 1000).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in the evidence for
the benefits was judged as very low because of indirectness and
imprecision of the estimates.
OTHERETDCRITERIAANDCONSIDERATIONS. The panel determined that there is
low-certainty evidence of a net health benefit from LMWH over no
thromboprophylaxis and concluded that the balance of effects
probably favors LMWH. The panel judged that resource require-
ments (and associated costs) varies and that the cost-effectiveness
is uncertain. The panel also agreed that acceptability varies; it may
depend on baseline risk for patients, being more acceptable for
patients with a higher risk for thrombosis. In the case of health care
professionals, it may also depend on the baseline risk of thrombosis.
Some clinicians may be concerned about cost-effectiveness and the
burden of prescribingwhen LMWH is not routinely covered by insurance
plans. Feasibility is likely to be reduced with LMWH.
Recommendations 18 and 19
For patients with cancer and a CVC, the ASH guideline panel
suggests not using parenteral or oral thromboprophylaxis
(conditional recommendation, low certainty in the evidence of
effects ÅÅ◯◯).
Remarks: The recommendation applies to fixed- and adjusted-
dose VKA. Thromboprophylaxis may be considered for se-
lected patients with cancer who are considered at high risk for
VTE or for patients receiving thalidomide-, lenalidomide-, or
pomalidomide-based regimens for myeloma.
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Oral thromboprophylaxis vs no thromboprophylaxis. SUMMARY
OF THE EVIDENCE. We identified 6 systematic reviews addressing this
question.264-269 The panel was not interested in fixed-dose VKA
because it does not reflect current practice. Thus, from the
identified systematic reviews, there was only 1 eligible RCT that
reported on adjusted-dose VKA and fulfilled our inclusion crite-
ria.277 Our systematic search of RCTs did not identify any additional
studies. This included trial reported the effect of adjusted-dose VKA
compared with no prophylaxis on mortality, symptomatic catheter-
related thrombosis, and major bleeding. VKA was adjusted to maintain
the international normalized ratio (INR) between 1.5 and 2.0. It was
administered 3 days prior to CVC insertion and continued until
thrombosis occurred or the catheter had to be removed for any
reason. The most common site of cancer was colorectal. The EtD
framework is available at https://guidelines.ash.gradepro.org/profile/
th_JPGUVWCE.
BENEFITS. Compared with no thromboprophylaxis, dose-adjusted
VKA may reduce mortality and symptomatic catheter-related
thrombosis, but the evidence is very uncertain. The panel judged
desirable effects as moderate (for mortality: RR, 0.91; 95% CI,
0.76-1.08; ARR, 35 fewer per 1000; 95% CI, 94 fewer to 31
more per 1000; for symptomatic catheter-related thrombosis:
RR, 0.46; 95% CI, 0.24-0.90; ARR, 15 fewer per 1000; 95% CI,
3-21 fewer).
HARMS AND BURDEN. Dose-adjusted VKA may increase major
bleeding, but the evidence is very uncertain. The panel judged
undesirable effects as moderate (for major bleeding: RR, 13.67;
95%CI, 1.82-102.60; ARI, 31 more per 1000; 95%CI, 2-251 more
per 1000).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in the evidence for
the benefits was judged as very low because of imprecision and
indirectness.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel determined that
there is very-low-certainty evidence of a net health harm from dose-
adjusted VKA over no thromboprophylaxis and concluded that the
balance of effects probably favors no thromboprophylaxis. The
panel perceived that the lower baseline risk of catheter-related
thrombosis with new catheters (,2.7%) will reduce the absolute
effects of VKA. The risk of bleeding was considered important and
outweighing the reduction in catheter-related thrombosis.
The panel judged that resource requirements and associated
costs are moderate and that the cost-effectiveness is un-
certain. The panel also agreed that equity will probably be
reduced because there are subgroups who would have
difficulty getting adequate VKA monitoring. Although dose-
adjusted VKA is probably acceptable to stakeholders, some
patients and/or caregivers might find the logistics for VKA
monitoring unacceptable.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. For
patients with cancer with a CVC, the ASH guideline panel suggests
not using LMWH or VKA as thromboprophylaxis. This recommen-
dation does not apply to patients who have a CVC, have a high or
intermediate risk for thrombosis, and are also receiving systemic
therapy (see Recommendations 13 and 15).
The conditional recommendation against the use of LMWH over no
thromboprophylaxis for patients with cancer with a CVC takes into
account that, although the benefit may favor LMWH, it is in the
context of low-certainty evidence, variable costs, no data available
on cost-effectiveness, and a probable reduction in equity.
The conditional recommendation against using adjusted-dose VKA
over no thromboprophylaxis for patients with cancer with a CVC is
due to a balance of effects that probably favors no thrombopro-
phylaxis in the context of low-certainty evidence, moderate costs,
and reduction in equity. Data on cost-effectiveness are not available.
The risk of bleeding was considered important and outweighing the
reduction in catheter-related thrombosis. The recommendation
applies to fixed-dose and adjusted-dose VKA. The panel agreed
that more research is needed, primarily about the use for high-risk
patients, treatment duration, and best agent (eg, DOACs).
Initial treatment (within first week) for patients
with cancer
Should LMWH vs UFH vs fondaparinux vs DOAC be used for
patients with cancer with VTE for initial treatment in the first week?
LMWH vs UFH. SUMMARY OF THE EVIDENCE. We identified 2
systematic reviews that partially addressed this question, including
1 review reporting outcomes for cancer patients.278,279 These
reviews included 14 trials.254,280-292 Our update of the systematic
review identified 1 additional trial that fulfilled the inclusion
criteria.293 All RCTs included hemodynamically stable patients
who did not require thrombolysis and compared initial treatment
with LMWH vs UFH administered during the first 10 days,
followed by VKA (target INR between 2 and 3), for the
management of acute DVT or PE. Given that all RCTs used VKA
during the follow-up period, the event rates for the total duration of
follow-up were used to assess the efficacy and safety of LMWH or
UFH for the initial treatment of VTE for this patient population.
Eleven trials reported on the effect of LMWH compared with UFH
Recommendations 20, 21, and 22
For patients with cancer and VTE, the ASH guideline panel
suggests that DOACs (apixaban or rivaroxaban) or LMWH be
used for initial treatment (conditional recommendation, very low
certainty in the evidence of effects Å◯◯◯). If a DOAC is not
used, the ASH guideline panel recommends LMWH over UFH
(strong recommendation, moderate certainty in the evidence of
effects ÅÅÅ◯) and LMWH over fondaparinux (conditional
recommendation, very low certainty in the evidence of effects
Å◯◯◯) for initial treatment of VTE for patients with cancer.
Remarks: The period of initial treatment is 5 to 10 days, covering
the early period of care starting from the time of diagnosis of VTE.
Only 2 DOACs (apixaban and rivaroxaban) have been approved
for the initial treatment period. DOACs should be used carefully for
patients with GI cancers because of the higher risk of GI bleeding.
UFH might be preferred over LMWH for the patient with cancer
with severe renal impairment (defined as creatinine clearance,30
mL/min). The use of fondaparinux might be considered for patients
with cancer and VTE and a history of HIT (see “American Society
of Hematology 2018 guidelines for the management of venous
thromboembolism: heparin-induced thrombocytopenia”).402
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on mortality,254,281-286,288-291 3 trials reported on recurrent
VTE,280,287,288 and none reported on major bleeding, quality-of-
life impairment, HIT, or chronic thrombotic pulmonary hypertension.
The EtD framework is available at https://guidelines.ash.grade-
pro.org/profile/F2xpTxLx5I8.
BENEFITS. LMWH probably results in a large reduction in mortality
and recurrent VTE, and the panel judged the effects to be large (for
mortality: RR, 0.75; 95% CI, 0.56-1.02; ARR, 46 fewer per 1000;
95% CI, 82 fewer to 4 more per 1000; for recurrent VTE: RR, 0.69;
95% CI, 0.27-1.76; ARR, 30 fewer per 1000; 95% CI, 70 fewer to
73 more per 1000).
HARMS AND BURDEN. Indirect data from surgical patients with cancer
suggest that there is no important difference in bleeding between
LMWH and UFH for thromboprophylaxis.294 Indirect data from
noncancer patients suggest that there is no important difference
between LMWH and UFH with respect to bleeding for initial
treatment, and a higher risk for HIT is associated with UFH.295
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as moderate because of imprecision of the
estimates. The panel decided not to rate down further for
indirectness, because there were enough data from thrombopro-
phylaxis for surgical patients with cancer.
OTHER ETD CRITERIA AND CONSIDERATIONS. The major driver of cost will
be the decision to provide initial treatment in the hospital or
ambulatory setting. Hospitalization for administration of UFH is
costly, and a reduction in cost with LMWH in the ambulatory
setting justifies a judgment of large cost savings, with cost-
effectiveness data favoring LMWH over UFH. Similarly, a lower
risk for suspected and confirmed HIT associated with LMWH use
will also result in cost savings. The panel noted that, in some
settings (eg, United States, as well as some patients in Canada),
patients may bear the cost of outpatient LMWH, whereas in other
countries (eg, the United Kingdom, Austria, and Spain) they will
not. LMWH was judged to be probably acceptable and feasible to
implement.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
strong recommendation (rather than conditional) for initial
treatment with LMWH over UFH for patients with cancer with
VTE in the first week was due to a balance of effects that favors
LMWH in the context of moderate-certainty evidence, large
savings, and cost-effectiveness that favors an intervention that is
acceptable and feasible.
UFH might be preferred over LMWH for the patient with cancer
with severe renal impairment (defined as creatinine clearance
,30 mL/min). LMWH is often preferred based on the ease and
frequency of administration; therefore, it might be easier to
implement in practice. With UFH there is a need for hospitaliza-
tion, continuous IV infusion, and repeat venipunctures to monitor
(anti–factor Xa or activated partial thromboplastin time) and adjust the
dose. Both require monitoring for the occurrence of active bleeding.
The panel does not consider this question comparing 2 parenteral
agents a research priority at this time.
Fondaparinux vs LMWH. SUMMARY OF THE EVIDENCE. No system-
atic review addressing this question was identified. Our systematic
search of RCTs identified 1 study that fulfilled the inclusion
criteria.296 This study is a post hoc (retrospective) subgroup
analysis of 2 previous RCTs with subsequent treatment with
VKAs.297,298 The investigators compared initial treatment with
fondaparinux vs LMWH administered for 5 to 10 days for the acute
treatment of DVT or PE. All participants received VKA therapy within
72 hours after commencing initial therapy, which continued for $3
months. Given that both RCTs used VKA for 3 months, the event
rates for the total duration of follow-up were used to assess the
efficacy and safety of LMWH and fondaparinux in this patient
population. The included study reported on the effect on mortality,
recurrent VTE, and major bleeding. All outcomes occurred after
treatment with LMWH or fondaparinux had been stopped. Even the
investigators recognize the severe limitations and that the results
should merely be considered hypothesis generating. Consequently,
our very low certainty in this evidence is reflected below. The EtD
framework is available at https://guidelines.ash.gradepro.org/pro-
file/JnUTLNyxQbY.
BENEFITS. The panel noted the lack of benefit and trivial desirable
effects of fondaparinux (compared with LMWH).
HARMS AND BURDEN. Fondaparinux may increase mortality and
probably increases recurrent VTE, and the panel judged the effects
to be large (for mortality: RR, 1.19; 95% CI, 0.67-2.11; ARI, 29
more per 1000; 95% CI, 51 fewer to 170 more per 1000; for
recurrent VTE: RR, 2.35; 95% CI, 0.95-5.79; ARI, 117 more per
1000; 95%CI, 34 fewer to 417 more per 1000 using a baseline risk
of 8.7%).299 No apparent differences were observed for the
outcome major bleeding (RR, 0.99; 95% CI, 0.40-2.48; ARR,
0 fewer per 1000; 95% CI, 22 fewer to 53 more per 1000 using
baseline risk of 3.6%).299
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as very low because of imprecision and
indirectness of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel noted that costs
may be moderate because of the higher cost associated with the
use of fondaparinux over LMWH. Despite important uncertainty and
limited direct data, the panel judged that the cost-effectiveness
probably favors LMWH. The impact of health equity is likely to vary,
because some patients might not be able to afford the interventions
if they have to pay for them (eg, in the United States). Both
interventions were judged to be probably acceptable and feasible to
implement.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
conditional recommendation for LMWH over fondaparinux for
patients with cancer and VTE for initial treatment of VTE in the first
week was due to a balance of effects that probably favors LMWH in
the context of very-low-certainty evidence, moderate costs, and cost-
effectiveness. The use of fondaparinux might be considered for
patients with cancer and VTE and a prior history of HIT (see
“American Society of Hematology 2018 guidelines for themanagement
of venous thromboembolism: heparin-induced thrombocytopenia”).402
The panel does not consider this question comparing 2 parenteral
agents a research priority at this time, despite the very low certainty
in the existing evidence. Current research priorities are the
comparative safety and efficacy of oral agents vs conventional
parenteral therapy.
DOAC vs LMWH. SUMMARY OF THE EVIDENCE. No systematic review
addressing this question was identified. Our systematic search of
RCTs identified 3 studies that fulfilled the inclusion criteria.300-302 Data
from 2 studies could be included in the analyses.300,301 Both studies
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included patients with active cancer who had VTE. One study also
included upper extremity DVT and splanchnic vein thrombosis. Both
studies reported on the effect of dalteparin on mortality, recurrent
VTE, and major bleeding during the first week compared with
rivaroxaban300 or apixaban.301 The EtD framework is available at
https://guidelines.ash.gradepro.org/profile/A4TBFFTabtU.
BENEFITS. Compared with LMWH, DOACs may reduce the risk of
recurrent VTE and major bleeding, but the evidence is very
uncertain, and the panel judged this effect to be small (for recurrent
VTE: RR, 0.20; 95% CI, 0.01-4.04; ARR, 11 fewer per 1000; 95%
CI, 14 fewer to 43 more per 1000; for major bleeding: RR, 0.33;
95% CI, 0.01-8.13; ARR, 2 fewer per 1000; 95% CI, 3 fewer to 21
more per 1000).
HARMS AND BURDEN. Compared with LMWH, DOACs may increase
mortality, but the evidence is very uncertain, and the panel judged
this effect to be small (for mortality: RR, 3.00; 95% CI, 0.12-73.21;
with only 1 death reported in the DOAC group [n 5 348] and
0 events occurring in the LMWH group [n 5 345]).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as very low because of the risk of bias and
imprecision of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. Based on the available
evidence, the balance of effects favors initial treatment with a
DOAC or LMWH. The panel considered that cost would vary
(LMWH at therapeutic doses is generally more expensive than
DOACs but it might depend on the country and setting) and that
there are no data on cost-effectiveness. Both options were
considered feasible and probably acceptable for most individuals
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS.
With no net benefit for 1 treatment option over the other, as well as
the variable cost and no data on cost-effectiveness, the panel
suggests using a DOAC (apixaban or rivaroxaban) or LMWH for
initial treatment for patients with cancer and VTE. The period of initial
treatment may range from 5 to 10 days, covering the early period of
care starting from the time of diagnosis of VTE. The choice of
treatment must be based on the specific clinical setting to minimize
risk, after careful consideration of bleeding risk, drug-drug interac-
tions, patient preference, and the availability of treatment options,
including cost considerations. DOACs should be used carefully for
patients with GI cancers because of the higher risk of GI bleeding
and for patients with prior upper GI resections.303
Short-term treatment for patients with active cancer
(initial 3-6 months)
Should LMWH, VKA, or DOAC be used for the short-term
treatment of VTE (first 3-6 months) for patients with active cancer?
LMWH vs VKA. SUMMARY OF THE EVIDENCE. We identified 11
systematic reviews addressing this question.304-313 From these
reviews, we identified 8 eligible RCTs that fulfilled our inclusion
criteria and measured outcomes relevant to this question.314-319 In
all studies, LMWH was administered over 3 to 6 months, and the
outcomes were assessed during that time frame. For patients
initiating VKA, bridging with a minimum of 5 days of LMWH or UFH
was required in 5 studies314,316-319 or 1 study,315 respectively. Four
studies reported on mortality,314,316-318 6 studies reported on
recurrent VTE,314-319 5 studies reported on major bleeding,314-318
and 1 study reported on HIT.314 The EtD framework is available at
https://guidelines.ash.gradepro.org/profile/O7wwrVBUfVU.
BENEFITS. Compared with VKA, LMWH probably results in little to no
difference in mortality and probably reduces recurrent VTE. The
panel judged the effects to be moderate (for mortality: RR, 1.00;
95% CI, 0.88-1.13; ARR, 0 fewer per 1000; 95% CI, 45 fewer to 48
more per 1000; for recurrent VTE: RR, 0.56; 95%CI, 0.42-0.74; ARR,
57 fewer per 1000; 95% CI, 34-76 fewer per 1000).
HARMS AND BURDEN. Compared with VKA, LMWH probably results in
little to no difference in major bleeding, and the panel judged the effects
to be trivial (for major bleeding: RR, 1.06; 95% CI, 0.64-1.77; ARI, 3
more per 1000; 95% CI, 17 fewer to 35 more per 1000).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as moderate because of the risk of bias and
imprecision of the estimates. The panel had a discussion about the
importance of HIT as an outcome for this particular clinical question.
The panel lowered the importance of HIT from “critical” to “important”
because it was believed that this outcome did not influence the
direction or the strength of the recommendation.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel considered that
resource requirements were moderate but noted a high level
of uncertainty, with lack of direct evidence for the comparisons
of resource utilization during this treatment period. The results of
the available cost-effectiveness analyses vary based on baseline
assumptions and input. Based on a NICE evaluation focusing on
the Aujesky et al 2005 study,320 the cost for 3 months of LMWH
will alter cost-effectiveness results and may reduce cost consider-
ably. Thus, treatment with LMWH may reduce inequity. LMWH was
also believed to be an intervention that is probably acceptable and
feasible.
Recommendations 23, 24, and 25
For the short-term treatment of VTE (first 3-6 months) for pa-
tients with active cancer, the ASH guideline panel suggests
DOAC (apixaban, edoxaban, or rivaroxaban) over LMWH
(conditional recommendation, low certainty in the evidence of
effects ÅÅ◯◯). DOAC is also suggested over VKA (condi-
tional recommendation, very low certainty in the evidence of
effectsÅ◯◯◯). If a DOAC is not used, the ASH guideline panel
suggests LMWH over VKA (conditional recommendation,
moderate certainty in the evidence of effects ÅÅÅ◯).
Remarks: DOACs should be used carefully for patients with GI
cancers because of the higher risk of GI bleeding. The choice of
treatment must be based on the specific clinical setting to min-
imize risk, after careful consideration of potential drug-drug in-
teractions, bleeding risk, patient preference, and the availability
of treatment options, including cost considerations. VKA is
generally preferred over LMWH and DOAC for patients with
cancer and severe renal impairment defined as creatinine
clearance,30 mL/min. The direct factor Xa inhibitors apixaban,
edoxaban, and rivaroxaban are the only DOACs that were eval-
uated for the short-term treatment of VTE for patients with
cancer. Different DOACs have different drug-drug interactions.
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CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS.
The conditional recommendation for LMWH over VKA for short-
term treatment (3-6 months) for patients with active cancer and VTE
was due to a balance of effects that probably favors LMWH in the
context of moderate-certainty evidence, uncertain and variable
resource use and cost-effectiveness, a probable reduction in inequity,
and an intervention that is probably acceptable and feasible.
VKA is generally preferred over LMWH for most patients with
cancer and severe renal impairment defined as creatinine clearance
,30 mL/min. Adherence may be a challenge when continuing daily
injections vs switching to an oral agent, even with routine monitoring.
Drug-drug interactions are common with VKA and often unpredict-
able for patients on multiagent chemotherapeutic regimens. VKA
should be accompanied by increased INR monitoring, especially for
patients on drugs that may alter pharmacokinetics and for patients
with significant GI toxicity (eg, nausea, vomiting, diarrhea, colitis) and
inconsistent dietary and alcohol habits.
As research priorities, the panel suggested identifying the agent of
choice to use for treatment and conducting cost-effectiveness
analyses exploring different combinations of treatment.
DOAC vs VKA. SUMMARY OF THE EVIDENCE. We identified 12
systematic reviews addressing this question.305,307,310,312,313,321-327
We considered only studies that provided results for patients with
active cancer at enrollment. From these reviews, we identified 3
post hoc analyses of 3 eligible RCTs that fulfilled our inclusion
criteria and measured outcomes relevant to this question.328-330
The 3 trials compared different DOACs (rivaroxaban, edoxaban, and
apixaban) with LMWH followed by VKA. All 3 RCTs reported on
mortality, recurrent VTE, and major bleeding. The EtD framework is
available at https://guidelines.ash.gradepro.org/profile/mNr37__9HdI.
BENEFITS. Compared with VKAs, DOACs may reduce mortality,
recurrent VTE, major bleeding, and quality-of-life impairment, and
the panel judged the effects to be moderate (for mortality: RR, 0.92;
95% CI, 0.68-1.69; ARR, 24 fewer per 1000; 95% CI, 98 fewer to
211 more per 1000 using a baseline risk of 30.6%316; for recurrent
VTE: RR, 0.56; 95% CI, 0.28-1.12; ARR, 44 fewer per 1000; 95%
CI, 72 fewer to 12 more per 1000 using a baseline risk of 10.4%316;
for major bleeding: RR, 0.68; 95% CI, 0.31-1.47; ARR, 8 fewer per
1000; 95% CI, 17 fewer to 11 more per 1000 using a baseline risk
of 2.4%316; for quality-of-life impairment, patients showed better
scores).329
HARMS AND BURDEN. Compared with VKA, DOACs had trivial undesir-
able effects other than in rare circumstances when plasma
concentration of DOACs might be helpful but not readily available.
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as low because of indirectness and imprecision
of the estimates. We rated down for indirectness because higher-
risk cancer patients were not included in the trials evaluating DOAC
vs VKA. Therefore, we used the best baseline risk from previously
reported studies. The time in the therapeutic range of VKAs in the
control arms of these studies varied, providing additional uncertainty
about the magnitude of the observed effects. We did not rate down
for risk of bias because the results were consistent across individual
trials with open-label and double-blinded design. We included
subgroups of patients with cancer from the different studies. We
did not consider this a potential risk for bias because these post hoc
analyses included large samples of patients with cancer, and other
patient characteristics were similar between the intervention and
control arms.
OTHER ETDCRITERIA ANDCONSIDERATIONS. The panel noted that the cost
of DOACs varies between settings. VKA cost is similar across
settings and is universally inexpensive, but resources for monitoring
(laboratory costs or time to review results) will be different. The
panel noted that these studies did not focus on patients with cancer
and that costs will likely vary across different health care settings.
The impact on equity will vary depending on access to DOACs and
differences in out-of-pocket costs across settings.
Although DOACs are orally administered without routine monitoring
and, therefore, are generally feasible, they are not appropriate for
some clinical settings (severe renal dysfunction defined as
creatinine clearance ,30 mL/min, pregnancy, drug-drug interac-
tions, upper GI resection) and may not be available in all clinical
practice settings. Although DOACs and VKAs are reasonably easy
to implement, DOACs are often preferred based on the ease of
administration (no need for laboratory monitoring); therefore, they
may be easier to implement in practice but probably are associated
with higher costs.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
conditional recommendation for short-term treatment with DOAC
over VKA for patients with active cancer and VTE to prevent VTE
recurrence is due to a probably favorable balance between
desirable and undesirable effects, in the context of low certainty in
the evidence (serious imprecision and serious indirectness),
variable resource use and cost-effectiveness, variable impact on
equity, and an intervention that is probably acceptable and
feasible.
The panel noted that, in this group of cancer patients, the overall
mortality is very different from the LMWH data305 and the Hokusai
VTE cancer data.330 These patients have about half of the mortality
risk compared with those populations. These studies included
earlier-stage cancer patients and a much healthier population with a
lower risk of recurrent VTE or bleeding complication than the
average cancer patient accounted in clinical practice.
Different DOACs have different drug-drug interactions.331 Further-
more, the availability and costs of rapid-reversal agents differ for
VKAs and DOACs. This might be an important consideration for
patients with a high risk for bleeding.
The panel does not consider this question a research priority at this
time.
DOAC vs LMWH. SUMMARY OF THE EVIDENCE. We identified 8
systematic reviews addressing this question.305,307,310,312,313,321,326,334
We considered only studies that provided results for patients with
active cancer at enrollment. From these reviews, we identified 4
eligible RCTs that fulfilled our inclusion criteria and measured
outcomes relevant to this question.300-302,333 All 4 RCTs reported
on recurrent VTE and major bleeding.300-302,333 The EtD
framework is available at https://guidelines.ash.gradepro.org/profile/
CNXrHZBGxHs.
BENEFITS. Compared with LMWH, DOACs (apixaban, edoxaban and
rivaroxaban) may reduce recurrent VTE, recurrent DVT, and
recurrent PE, and the panel judged the effects to be moderate
(for recurrent VTE: RR, 0.62; 95%CI, 0.43-0.90; ARR, 32 fewer per
1000; 95% CI, 8-47 fewer per 1000; for recurrent DVT: RR, 0.62;
95% CI, 0.38-0.99; ARR, 15 fewer per 1000; 95% CI, 0-24 fewer
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per 1000; for recurrent PE: RR, 0.71; 95% CI, 0.49-1.02; ARR, 13
fewer per 1000; 95% CI, 1-24 fewer per 1000).
HARMS AND BURDEN. Compared with LMWH, DOACs (apixaban,
edoxaban, and rivaroxaban) may increase major bleeding, and the
panel judged the effects to be small (for major bleeding: RR, 1.31;
95% CI, 0.83-2.02; ARI, 10 more per 1000; 95% CI, 6 fewer to
36 more per 1000). The risk of bleeding associated with DOACs
appears to vary with cancer type and the type of DOAC; a
threefold to fourfold higher risk is reported for patients with GI
cancers.336
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as low because of risk of bias and imprecision of
the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. No study of resource
utilization was available, and the panel noted that resource use
varies, depending on the risk of major bleeding, settings, and
populations. Only cost-effectiveness data from the general pop-
ulation were available. Equity might vary depending on access to
the drug because DOACs might not be widely available. The
interventions are probably acceptable and feasible to implement.
Although DOACs are orally administered without routine monitoring
and, therefore, are generally feasible, they are not appropriate for
some clinical settings (severe renal dysfunction defined as
creatinine clearance ,30 mL/min, pregnancy and lactation, drug-
drug interactions), and they may not be available in all clinical
practice settings.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. For
patients with active cancer and VTE, the ASH guideline panel
suggests using DOACs (apixaban, edoxaban, and rivaroxaban) over
LMWH for short-term treatment to prevent recurrent VTE. The
conditional recommendation was a result of a probably favorable
balance between desirable and undesirable effects, in the context
of low certainty in the evidence and uncertainty in the relative cost-
effectiveness.
Decisions about the type of anticoagulant should take into
consideration drug-drug interactions because different DOACs
have different drug-drug interactions. The choice of treatment
must also be based on the specific clinical setting to minimize
risks, patient preference to ensure adherence with recom-
mended treatment, and the availability of treatment options,
including cost considerations. The direct factor Xa inhibitors
apixaban, edoxaban, and rivaroxaban are the only DOACs that
were evaluated for the short-term treatment of VTE in patients
with cancer. There are no data for the direct thrombin inhibitor
dabigatran for this indication. There are also potential concerns
for higher bleeding rates in patients with GI cancers using a
DOAC.336 Therefore, DOACs should be used very carefully in
this patient population.
Additional studies comparing different DOACs (specifically the
direct thrombin inhibitor) with LMWH are warranted. Similarly, more
studies with patients with severe thrombocytopenia, hematological
malignancies, or unusual site thrombosis are needed.
Should short-term (first 3-6 months) treatment vs observation be
used for patients with incidental (unsuspected) PE?
Should short-term (first 3-6 months) treatment vs observation be
used for patients with SSPE?
Should short-term (first 3-6 months) treatment vs observation be
used for patients with visceral/splanchnic vein thrombosis?
Short-term (first 3-6 months) treatment vs observation
for patients with cancer and incidental (unsuspected)
PE. SUMMARY OF THE EVIDENCE. We did not identify any systematic
review or RCT that addressed this question. A pooled analysis of
individual patient data, including a total of 926 patients with cancer
and incidental PE from 11 cohorts, was identified.335 This study
presented the effect of LMWH compared with observation on the
weighted 6-month risks of mortality, recurrent VTE, and major
bleeding. Our search also identified 2 additional cohorts that fulfilled
the inclusion criteria.303,336 One cohort study included 715 patients
with active cancer diagnosed with incidental PE from the RIETE
(Registro Informatizado de Enfermedad Trombo Embólica) registry,
of which 98% were initially started on LMWH and 86% remained
on LMWH for short-term treatment.336 The other cohort study is
an international prospective cohort of 695 patients with active
cancer and a recent diagnosis of incidental PE, of which 97%
received anticoagulant therapy.303 Both cohort studies compared
the effect of continuing anticoagulation (mean follow-up of 235
days336 and median follow-up of 216 days303) vs discontinuing
anticoagulation (mean follow-up of 117 days) on mortality, recurrent
VTE, and major bleeding. These 2 cohorts provided the main source
of data for this analysis. The EtD framework is available at https://
guidelines.ash.gradepro.org/profile/HK7prWM9WvI.
BENEFITS. Short-term treatment with anticoagulation compared with
observation may reduce mortality, symptomatic PE, and symptom-
atic recurrent DVT, but the evidence is very uncertain, and the panel
Recommendations 26, 27, and 28
For patients with cancer and incidental (unsuspected) PE or
SSPE, the ASH guideline panel suggests short-term anti-
coagulation treatment rather than observation (conditional
recommendation, very low certainty in the evidence of effects
Å◯◯◯).
For patients with cancer and visceral/splanchnic vein throm-
bosis, the ASH guideline panel suggests treating with short-
term anticoagulation or observing (conditional recommenda-
tion, very low certainty in the evidence of effects Å◯◯◯).
Remarks: Clinicians should use clinical judgment when
considering anticoagulation for incidental PEs, SSPEs, or
splanchnic vein thrombosis. Factors that should be considered
include diagnostic certainty, chronicity (age of thrombus), ex-
tent of thrombosis, associated symptoms, and bleeding risks.
Caution should be observed to ensure a favorable balance of
benefits vs harms when anticoagulating patients with a higher
bleeding risk. The choice of anticoagulant (eg, LMWH, VKA, or
DOACs) should also depend on a patient’s underlying risk for
bleeding. If therapeutic anticoagulation is warranted, the ASH
guideline panel recommends the use of the same anticoagu-
lants recommended for cancer-associated thrombosis (see the
questions associated with Recommendations 23, 24, and 25
[DOACs vs LMWH vs VKAs for short-term treatment]). If long-
term anticoagulation is considered, please see long-term
treatment recommendations.
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judged these benefits to be large (for mortality: RR, 0.81; 95% CI,
0.67-0.98; ARR, 89 fewer per 1000; 95%CI, 9-155 fewer per 1000
using a baseline risk of 47%335; for symptomatic PE: RR, 0.36; 95%
CI, 0.18-0.72; ARR, 77 fewer per 1000; 95% CI, 34-98 fewer per
1000 using a baseline risk of 12%335; for symptomatic recurrent DVT:
RR, 0.19; 95% CI, 0.08-0.48; ARR, 97 fewer per 1000; 95% CI, 62-
110 fewer per 1000 using a baseline risk of 12%).335
HARMS AND BURDEN. Compared with observation, short-term treat-
ment may increase major bleeding, but the evidence is very
uncertain, and the panel judged it to be large (for major bleeding:
RR, 3.00; 95% CI, 1.21-7.47; ARI, 128 more per 1000; 95% CI,
13-414 more per 1000 using a baseline risk of 6.4%335).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects based on observational studies was judged as very low because
of a risk of bias, inconsistency, and imprecision of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel noted that costs
may be moderate as a result of the cost associated with short-term
treatment of all incidental PEs and the increase in major bleeding
(despite the savings in events prevented). No cost-effectiveness
information is available. The impact of health equity is likely to vary
because some patients might not be able to afford the interventions
if they have to pay for them (eg, in the United States). Short-term
treatment was judged to be probably acceptable and feasible to
implement.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
conditional recommendation for short-term treatment over obser-
vation for patients with cancer and incidental PE was due to a
balance of effects that probably favors treatment in the context of
very-low-certainty evidence and moderate costs. The panel noted
that caution should also be observed to ensure a favorable
balance of benefits vs harms when anticoagulating patients with a
higher bleeding risk. The choice of anticoagulant (eg, LMWH, VKA,
or DOACs) should also consider a patient’s underlying risk for
bleeding. Patient preference will be an important factor given the
need for daily treatment and any potential need for interruption of
cancer treatment.
The panel noted that because of the very low certainty about the
evidence of effects, this question in the cancer patient population
with incidental PEs should be a research priority.
Short-term (first 3-6 months) treatment vs observation
for patients with cancer and SSPE. SUMMARY OF THE EVIDENCE.
We did not identify any systematic reviews or RCTs that addressed
this question. Our systematic search identified 9 observational
studies that fulfilled, in part, the inclusion criteria.303,337-344 The
certainty in the evidence from these observational studies of
patients with single or multiple SSPEs was judged to be very low
and was considered unreliable. Thus, the panel relied on indirect
evidence from other populations. The EtD framework is available at
https://guidelines.ash.gradepro.org/profile/uQTREWSCBho.
BENEFITS. The panel relied on indirect evidence from other populations
because the quality of observational studies for patients with cancer
with single or multiple SSPEs was judged to be very low and was
considered unreliable. Overall, the results showed a reduction in risk
of recurrent VTE. This indirect evidence suggests that patients with
single or multiple SSPEs may benefit from anticoagulation therapy
(rather than observation), especially if they are at moderate/high risk
for recurrent VTE and have a lower risk for major bleeding.
HARMS AND BURDEN. The guideline panel considered that the risk
of major bleeding was probably moderate considering that
cancer patients with VTE treated with LMWH for up to 6
months showed a risk of 7.7%,299 whereas a systematic review
of cohort and RCTs in noncancer patients with PEs treated with
anticoagulation therapy showed a risk for major bleeding of 1.8%
(1.1-2.6%).345
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects based on observational studies was judged as very low
because of risk of bias, inconsistency, indirectness, and imprecision
of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. Despite the high uncer-
tainty, the panel agreed that the desirable effects are likely to be
larger than the undesirable; hence, the balance of effects
probably favors short-term treatment vs observation. The panel
was unable to judge the resources required because of the high
uncertainty about the evidence of effects. No cost-effectiveness
information was available. The impact of health equity is likely to
vary, because some patients might not be able to afford the
interventions if they have to pay for them (eg, in the United
States). Treatment was judged to be probably acceptable and
feasible to implement.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS.
The conditional recommendation for short-term treatment over
observation for patients with single or multiple SSPEs was due to a
balance of effects that probably favors treatment in the context of
very-low-certainty evidence and moderate costs. For patients with a
single SSPE and no concomitant DVT, the possibility of a false-
positive computed tomography scan should be considered along
with the uncertain benefits of treatment and the increased risk of
major bleeding.
Patient preferences will be an important factor, given the need for
daily treatment and any potential need for interruption of cancer
treatment. The panel noted that because of the very low certainty
about the evidence of effects, this question should be a research
priority in cancer patients with SSPEs.346
Short-term (first 3-6 months) treatment vs observation
for patients with cancer and visceral/splanchnic vein
thrombosis. SUMMARY OF THE EVIDENCE. We did not identify any
systematic review or RCT that addressed this question. Our
systematic search identified 5 observational studies that reported, in
part, on anticoagulation in cancer patients with incidental and
symptomatic visceral/splanchnic vein thrombosis.347-351 Three of
these studies did not provide sufficient data.348,349,351 The other 2
articles are reports of the same study from the Registry on Splanchnic
Vein Thrombosis.347,350 The certainty in the evidence from this
observational study of patients with visceral/splanchnic vein throm-
bosis was judged to be very low and was considered inadequate to
determine the optimum approach to the management of these
patients, particularly with regard to the need for therapeutic
anticoagulation. Thus, to determine the potential benefits and harms
of anticoagulation therapy in this patient population, the panel took
into consideration 1 study that evaluated the safety of LMWH in
cancer patients with VTEs298 and a systematic review of patients with
symptomatic VTEs who received anticoagulation therapy for $3
months.345 It should be noted that neither of these studies examined
patients with splanchnic vein thrombosis. The EtD framework is
available at https://guidelines.ash.gradepro.org/profile/OYY_yPXFMHE.















E user on 12 February 2021
BENEFITS. The panel noted the high uncertainty in the available data
about the magnitude of the benefits (refer to the above summary for
more details).
HARMS AND BURDEN. The panel noted the high uncertainty in the
available data about the magnitude of the harms. The guideline
panel considered that the risk of major bleeding was 7.7% in cancer
patients with acute VTEs treated with LMWH for 6 months.298
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects based on observational studies was judged as very low
because of indirectness and imprecision of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. With the high uncertainty in
the evidence, the panel agreed that the balance of desirable and
undesirable effects is not known. The panel was unable to judge
the resources required because of the high uncertainty about
the evidence of effects. No cost-effectiveness information was
available. The impact of health equity is likely to vary, because
some patients might not be able to afford the interventions if they
have to pay for them (eg, in the United States). Treatment in these
patients was judged to be probably acceptable and feasible to
implement.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. There is
inadequate evidence available to determine the optimum manage-
ment of visceral/splanchnic vein thrombosis in patients with cancer,
particularly with regard to the need for therapeutic anticoagulation.
The conditional recommendation for short-term treatment with
anticoagulants or observation for patients with visceral/splanchnic
vein thrombosis is due to the unknown balance of effects between
treatment and observation in the context of very-low-certainty
evidence of effects and about costs. However, clinicians should consider
a number of factors in their treatment decision, including diagnostic
certainty, chronicity, extent of thrombosis, associated symptoms, and
bleeding risks. Patient preferences will be an important factor given the
need for daily treatment and potential need for interruption of cancer
treatment. More research is needed because no RCT and few cohort
studies focus on anticoagulation in the setting of visceral/splanchnic
vein thrombosis diagnosed incidentally in cancer patients.
Should keeping aCVC in place vs removing aCVCbe used for patients
with cancer and CVC-related VTEs on anticoagulant treatment?
Keeping CVC vs removing CVC. SUMMARY OF THE EVIDENCE.
No systematic review or RCT addressing this question was found. Our
systematic search identified 2 case series that reported on removing
the CVC as the outcome and not the intervention of interest to the
guideline question.352,353 One study followed 70 cancer patients
with CVC-related symptomatic DVTs receiving DOACs for 12
weeks.352 The second study followed 74 adults cancer patients
with CVC-related symptomatic DVTs receiving LMWH or VKA for
12 weeks.353 Both studies were considered case series (no direct
control). The studies found that none of the patients had the CVC
removed because of thrombosis. The EtD framework is available at
https://guidelines.ash.gradepro.org/profile/523QHQAYXeQ.
BENEFITS. The panel considered keeping the CVC to have a large
benefit compared with removing it in patients who are receiving
anticoagulation.
HARMS AND BURDEN. The panel considered the harms and burden to
be small.
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects based on observational studies was judged as very low because
of the risk of bias, indirectness, and imprecision of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. Despite the high uncertainty
in the evidence, the panel agreed that the desirable effects are likely
to be larger than the undesirable effects; hence, the balance
probably favors keeping the CVC. The panel believed that the
intervention (keeping the catheter) will be associated with less
resources than the comparator, because insertion of another CVC
will likely be required in the setting of ongoing anticancer treatment (eg,
chemotherapy or transfusion). The intervention probably has no impact
on equity, is probably acceptable, and is feasible to implement.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS.
Despite the very low certainty in the evidence, the panel was reassured
that there were low rates of recurrent VTEs that did not appear to be
different from the baseline rates. The conditional recommendation for
keeping a CVC over removing a CVC in patients with cancer and
CVC-related VTEs receiving anticoagulation is due to a balance of
effects that probably favors keeping it in the context of moderate cost
savings and probably no impact on equity. Monitoring for resolution of
symptoms and concomitant signs of infection is warranted.
Comparative observational or interventional studies are needed
because of the very low certainty about the evidence of effects.
Should increasing the dose of LMWH to supratherapeutic levels vs
continuing a standard therapeutic dose be used for patients with
active cancer and recurrent VTEs, despite therapeutic anticoagu-
lation treatment?
Recommendation 29
For patients with cancer with CVC-related VTE receiving
anticoagulant treatment, the ASH guideline panel suggests
keeping the CVC over removing the CVC (conditional recom-
mendation, very low certainty in the evidence of effectsÅ◯◯◯).
Remarks: If a VTE develops and the CVC is left in place, anti-
coagulation is required. The choice of treatment must be based
on the specific clinical setting to minimize risk, after careful
consideration of bleeding risk, drug-drug interactions, patient
preference, and the availability of treatment options, including
cost considerations. Patients with infected, mispositioned, or
malfunctioning CVCs or those no longer requiring their CVC
should have it removed. Similarly, patients who cannot receive
anticoagulant treatment (eg, severe refractive thrombocytopenia,
bleeding) may need CVC removal if not required for optimal care.
Recommendation 30
For patients with cancer and recurrent VTEs, despite receiving
therapeutic LMWH, the ASH guideline panel suggests in-
creasing the LMWH dose to supratherapeutic levels or con-
tinuing with a therapeutic dose (conditional recommendation,
very low certainty in the evidence of effects Å◯◯◯).
Remarks: Supratherapeutic dosing of LMWH should be
considered carefully for patients with a high risk for bleeding.
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Increasing dose to supratherapeutic levels vs continu-
ing with standard therapeutic dose. SUMMARY OF THE EVIDENCE.
We did not identify any systematic review or RCT that addressed
this question. Our systematic search identified 3 observational studies
that partially fulfilled the inclusion criteria.354-356 The certainty in the
evidence from these observational studies was judged to be very low
and was considered unreliable. Thus, the panel relied on indirect
evidence from studies of VKAs in other high-risk patient populations
(antiphospholipid antibody syndrome357 and mechanical valve
disease).358,359 The EtD framework is available online at https://
guidelines.ash.gradepro.org/profile/qG3RaTEAXEQ.
BENEFITS. The panel considered that, from a biochemical perspec-
tive, it makes sense to provide a higher concentration of an
anticoagulant for patients generating greater levels of thrombin or
patients with heightened nonspecific binding of LMWH. However, the
panel considered that the efficacy and safety of increasing the LMWH
dose to supratherapeutic levels in cancer patients with recurrent VTEs,
despite therapeutic LMWH, are unknown and that the evidence of the
effect is very uncertain.
HARMS AND BURDEN. The panel considered that, given the lack of
evidence, any effect is very uncertain.
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects based on observational studies was judged as very low owing to
the risk of bias, indirectness, and imprecision of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel was unable to
judge the resources required because of the high uncertainty about
the evidence of effects. No cost-effectiveness information was
available. The intervention probably would have no impact on health
equity. Treatment in these patients was judged to be probably
acceptable and probably feasible to implement.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
conditional recommendation for optimizing the LMWH dose to
supratherapeutic levels or continuing on a therapeutic dose for patients
with cancer and recurrent VTEs receiving therapeutic LMWH is due
to an unclear balance between desirable and undesirable effects.
Supratherapeutic dosing of LMWH may pose an unacceptable risk
for patients with a high risk for bleeding. Comparative observational
or interventional studies are needed because of the very low certainty
about the evidence of effects. Only a few cohort studies focusing on
recurrent VTEs during LMWH are available, whereas no study has
assessed the management of recurrent VTEs despite DOACs.
Should an IVC filter be used or not in patients with cancer with
recurrent VTEs, despite anticoagulation treatment?
Adding an IVC filter vs not in patients with cancer and
recurrent VTEs, despite anticoagulation treatment. SUMMARY
OF THE EVIDENCE. We did not identify any systematic review or RCT that
addressed this question. Our systematic search identified 1 observa-
tional study that fulfilled, in part, the inclusion criteria.364 This
international registry within the International Society on Throm-
bosis and Haemostasis explored how the different antithrom-
botic regimens were used to manage patients with cancer and
recurrent VTEs, despite anticoagulation treatment. The EtD
framework is available at https://guidelines.ash.gradepro.org/
profile/JCgX8Z1ru8g.
BENEFITS. Adding an IVC filter vs not in patients with cancer and
recurrent VTEs, despite anticoagulation, did not show any
apparent benefits (recurrent PE), but the evidence is very
uncertain. The panel judged this potential desirable effect to be
trivial.
HARMS AND BURDEN. Adding an IVC filter vs not in patients with
cancer and recurrent VTEs, despite anticoagulation, may
increase the risk of mortality, second recurrent VTE, and major
bleeding; the panel judged these effects to be large. However,
the evidence is very uncertain (for mortality: RR, 1.36, 95% CI,
0.69-2.68; ARI, 132 more per 1000; 95% CI, 114 fewer to 618
more per 1000; for second recurrent VTE: RR, 5.80, 95% CI,
1.96-17.13; ARI, 331 more per 1000; 95% CI, 66-1000 more
per 1000; for major bleeding: RR, 2.90; 95% CI, 0.94-8.99; ARI,
197 more per 1000; 95% CI, 6 fewer to 827 more per 1000).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these
estimated effects based on observational studies was judged
as very low because of the risk of bias and imprecision of the
estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. The panel judged the
resources required as moderate, despite the lack of studies,
and judged that the cost-effectiveness probably favors not
inserting an IVC filter in this population. The intervention probably
would have no impact on health equity. Treatment in these
patients was judged to be probably acceptable, although the
feasibility may vary because IVC filters may not be accessible or
possible in all centers.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
conditional recommendation against adding an IVC filter in
patients with cancer and recurrent VTEs, despite anticoagulant
treatment, is due to a balance of effects that probably favors not
adding an IVC filter in the context of very low certainty about the
effects, as well as the fact that cost-effectiveness probably
favors not adding an IVC filter. Comparative observational or
interventional studies are needed because of the very low
certainty about the evidence of effects.
Long-term treatment (>6 months) for patients with
active cancer and VTE
Should long-term (.6 months) anticoagulation vs short-term
(3-6 months) anticoagulation be used for secondary pro-
phylaxis for patients with active cancer and VTEs?
Should indefinite anticoagulation be continued vs stopped after
completion of a definitive period of anticoagulation?
Recommendation 31
For patients with cancer and recurrent VTEs, despite anti-
coagulation treatment, the ASH guideline panel suggests not
using an IVC filter over using a filter (conditional recommen-
dation, very low certainty in the evidence of effects Å◯◯◯).
Remarks: An IVC filter may be required if there is a contrain-
dication to anticoagulation therapy (active bleeding or urgent
surgery required). If an IVC filter is required, a retrievable filter is
preferred, and it should be removed once anticoagulation can
be safely resumed.
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Should DOACs vs LMWH be used for long-term (.6 months)
anticoagulation for patients with active cancer and VTEs?
Long-term anticoagulation (>6 months) vs short-term
anticoagulation (3-6 months). SUMMARY OF THE EVIDENCE.
We did not find any systematic review addressing this question.
Two single-arm cohort studies assessing the safety and efficacy of
LMWH for long-term use (up to 12 months) were identified.299,360
One trial included a second randomization, after the initial 6 months
of anticoagulation treatment, of patients with cancer with PEs or
residual venous obstruction to receive long-term DOACs or
observation (#12 months).361 However, because of the lack of
direct evidence for comparisons for the cohort studies and the very
small sample size (N 5 92) and number of events in this trial, the
guideline panel decided to include evidence from 10 trials
conducted in the general population from the “American Society
of Hematology 2020 guidelines for management of venous
thromboembolism: treatment of deep vein thrombosis and pulmo-
nary embolism.”403 Nineteen systematic reviews362-380 and 13
RCTs381-393 (N 5 8593) were identified to inform this recommen-
dation. Trials included adults with objectively confirmed DVTs or
PEs who had been treated with DOACs, LMWH, VKAs, or ASA for
$3 months without subsequent recurrence. The panel decided not
to include ASA as an intervention of interest, and 1 RCT was
excluded.393 Patients who received short-term anticoagulation
were randomized to receive placebo or continue long-term
treatment for $6 months. The mean follow-up time ranged from
24 to 28 months for different outcomes. The outcomes were
measured in both groups until the end of the extended-duration
treatment. The EtD framework is available at https://guide-
lines.ash.gradepro.org/profile/mtyOjXF7LTk.
BENEFITS. Long-term anticoagulation (.6 months) had no impact on
mortality and may decrease recurrent VTEs, PEs, and all DVTs. The
panel judged the effect to be moderate (for mortality: RR, 1.38;
95% CI, 0.85-2.23; ARI, 9 more per 1000; 95% CI, 4 fewer to 30
more per 1000; for recurrent VTE: RR, 0.54; 95% CI, 0.23-1.27;
ARR, 51 fewer per 1000; 95% CI, 85 fewer to 30 more per 1000
using a baseline risk of 11.1%299; for PE: RR, 0.66; 95% CI, 0.29-
1.51; ARR, 38 fewer per 1000; 95% CI, 79 fewer to 57 more per
1000 using a baseline risk of 11.1%299; for all DVTs: RR, 0.50; 95%
CI, 0.27-0.95; ARR, 56 fewer per 1000; 95% CI, 6-81 fewer per
1000 using a baseline risk of 11.1%).299 In 1 trial that directly
compared long-term vs short-term anticoagulation for secondary
prophylaxis specifically for patients with cancer and PEs or
residual vein obstruction (up to 12 months), long-term anti-
coagulation for secondary prophylaxis was associated with a
lower rate of recurrent VTEs (hazard ratio [HR]: 0.32; 95% CI,
0.06-1.58), without an increased rate of major bleeding compli-
cations (no event occurring in either group: DOACs, n 5 46 and
no treatment n 5 46).361
HARMS AND BURDEN. Long-term anticoagulation may increase major
bleeding (for major bleeding: RR, 1.25; 95% CI, 0.68-2.30; ARI, 26
more per 1000; 95% CI, 33 fewer to 133 more per 1000 using a
baseline risk of 10.2%).299
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as low because of indirectness and imprecision
of the estimates. The certainty in the evidence for the only available
trial was judged as low because of serious imprecision and
indirectness.
OTHER ETD CRITERIA AND CONSIDERATIONS. There was only 1 trial directly
comparing long-term vs short-term anticoagulation for secondary
prophylaxis specifically for patients with cancer and PEs or residual
vein obstruction.361 Because of its very low certainty, the panel
relied on additional indirect evidence from trials conducted with
patients without cancer. Therefore, there is uncertainty related to
the balance of benefits and harms in continuing anticoagulation
beyond 6 months in this setting.
The panel assumed that the costs were moderate and that the cost-
effectiveness would vary. Although the panel assumed that the
impact on health equity would vary, the use of long-term anti-
coagulation was considered acceptable and feasible.
It is important that clinicians use their best judgment based on
experience and their knowledge of the patient’s specific clinical
situation (eg, cancer, treatment, comorbidities) and consider the
patient’s values and preferences. Routine and regular assessment
of the likely benefits and harms of continued anticoagulation are
essential because the disease status and patient preferences may
change over time. At all times, the added risk for recurrent VTE, as
Recommendations 32, 33, and 34
For patients with active cancer and VTEs, the ASH guideline
panel suggests long-term anticoagulation for secondary pro-
phylaxis (.6 months) rather than short-term treatment alone (3-
6 months) (conditional recommendation, low certainty in the
evidence of effects ÅÅ◯◯).
For patients with active cancer and VTEs receiving long-term
anticoagulation for secondary prophylaxis, the ASH guideline
panel suggests continuing indefinite anticoagulation over
stopping after completion of a definitive period of anti-
coagulation (conditional recommendation, very low certainty in
the evidence of effects Å◯◯◯).
For patients with active cancer and VTEs requiring long-
term anticoagulation (.6 months), the ASH guideline
panel suggests using DOACs or LMWH (conditional rec-
ommendation, very low certainty in the evidence of effects
Å◯◯◯).
Remarks: Long-term anticoagulation for secondary VTE
prophylaxis should be considered for patients with active
cancer. In the absence of contraindications to anti-
coagulation, such as major bleeding, the panel concluded
that the benefits of long-term anticoagulation outweigh the
harms.
Long-term anticoagulation can be discontinued when pa-
tients are no longer at high risk for recurrent VTEs or if pa-
tients are entering the last weeks of life. The decision to use
long-term anticoagulation will depend on the type and stage
of cancer (eg, metastatic or not), overall prognosis, periodic
reevaluations of the risk of recurrent VTE and bleeding,
comorbidities, costs and patients’ preferences. The choice of
anticoagulant must also be based on the specific clinical
setting to minimize risk, after careful consideration of bleeding
risk, drug-drug interactions, patient preference, and the avail-
ability of treatment options, including cost considerations.
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well as bleeding associated with active cancer and cancer
therapies, should be considered when evaluating the balance of
benefits and harms associated with continued anticoagulation. This
is particularly pertinent to patients in the last weeks of life. One
observational study followed 214 cancer patients receiving
treatment for VTEs.394 The majority remained anticoagulated up
to the point of death, and this was associated with a clinically
relevant bleeding rate of 7% in the last week of life.394 A larger
observational study of 1079 cancer patients, 95% with a
Karnofsky score ,50, admitted to specialist palliative care
units reported a clinically relevant bleeding rate of 9.8% (95%
CI, 8.3-11.6).99 Bleeding was strongly associated with antico-
agulant and platelet transfusion (HR, 1.48; 95% CI, 1.02-2.15
and HR, 1.67; 95% CI, 1.15-2.44), respectively. These data
would support stopping anticoagulants and antithrombotics as
death approaches.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
panel determined that there is low certainty in the evidence for a net
health benefit from using long-term anticoagulation for secondary
prophylaxis over short-term anticoagulation for patients with active
cancer at high risk for recurrent VTEs. Despite the moderate costs,
the panel made a conditional recommendation in favor of long-term
anticoagulation over short-term anticoagulation in this patient
population.
The panel believed that secondary prophylaxis should be consid-
ered in cancer patients at high risk for recurrent VTEs, including
those receiving palliative-intent anticancer treatment, those in whom
treatment has not been curative (eg, recurrent or progressive
disease), and those in whom anticancer treatment is ongoing.395 In
the absence of a contraindication to anticoagulation because of
major bleeding, the panel has concluded that the benefits of
continued anticoagulation outweigh the harms. Decisions for
patients with cancer to continue long-term anticoagulation should
weigh the benefits and harms and integrate the person’s values and
preferences for the important outcomes and alternative manage-
ment strategies.
The panel identified this as an important knowledge gap for which
additional data are needed.
Continuing indefinite anticoagulation vs stopping after
completion of a definitive period of anticoagulation. SUMMARY
OF THE EVIDENCE. We did not find any systematic review or trial
addressing this question. Two prospective single-arm cohort
studies assessing the safety and efficacy of LMWH for long-term
use (#12 months) were identified.299,360 However, because of
the lack of direct evidence for comparisons, the guideline panel
decided to include evidence from 8 trials conducted in the
general population from the “American Society of Hematology
2020 guidelines for management of venous thromboembolism:
treatment of deep vein thrombosis and pulmonary embolism.”403
Nineteen systematic reviews362-380 and 13 RCTs381-393 (N 5
8593) were identified to inform this recommendation. Trials
included adults with objectively confirmed DVTs or PEs who had
been treated with DOACs, LMWH, VKAs or ASA for $3 months
without subsequent recurrence. The panel decided not to
include ASA as an intervention of interest, and 1 RCT was
excluded.393 Patients who received short-term anticoagulation
were randomized to receive placebo or to continue long-term
treatment of $6 months. The mean follow-up time ranged from
24 to 28months for different outcomes. The outcomesweremeasured
in both groups until the end of the extended-duration treatment. The
EtD framework is available at https://guidelines.ash.gradepro.org/
profile/Av-arKu5_7w.
BENEFITS. An indefinite duration of anticoagulation for secondary
prophylaxis compared with stopping after a definitive period of
anticoagulation had no impact on mortality and may reduce
recurrent VTEs, PEs, and all DVTs. The panel judged the effect to
be moderate (for mortality: RR, 0.70; 95% CI, 0.45-1.09; ARR, 5
fewer per 1000; 95% CI, 8 fewer to 1 more per 1000; for recurrent
VTE: RR, 0.20; 95% CI, 0.11-0.38; ARR, 89 fewer per 1000; 95%
CI, 69-99 fewer per 1000 using a baseline risk of 11.1%299; for PE:
RR, 0.23; 95% CI, 0.12-0.44; ARR, 85 fewer per 1000; 95% CI,
62-98 fewer per 1000 using a baseline risk of 11.1%299; for all
DVTs: RR, 0.16; 95%CI, 0.11-0.22; ARR, 93 fewer per 1000; 95%
CI, 87-99 fewer per 1000 using a baseline risk of 11.1%).299
HARMS AND BURDEN. An indefinite duration of anticoagulation for
secondary prophylaxis compared with stopping after a definitive
period of anticoagulation increased the risk of major bleeding. The
panel judged the effect to be small (for major bleeding: RR, 2.21;
95%CI, 1.42-3.44; ARI, 123 more per 1000; 95%CI, 43-249 more
per 1000 with a baseline risk of 10.2%).299
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as low owing to very serious indirectness of the
estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. No direct data for cost-
effectiveness of indefinite duration over limited duration of anti-
coagulation were available. Three reports from the general
population concluded that long-term anticoagulation strategies
are likely to be cost-effective. However, the panel judged cost-
effectiveness to be variable. Equity and acceptability were also
judged to be variable. An indefinite strategy was judged to be
probably feasible.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS.
The panel determined that there is low certainty in the evidence for a
net health benefit from using an indefinite duration of anti-
coagulation for secondary prophylaxis over a defined duration for
patients with active cancer and VTEs. Instead of a defined treatment
duration, the panel believed that long-term anticoagulation for
secondary prophylaxis can be discontinued when patients are no
longer at high risk for recurrent VTEs. The decision on indefinite
anticoagulation will be dependent on the type of cancer, prognosis,
and periodic reevaluation of the risk of thrombosis and bleeding,
comorbidities, cancer status, costs, and patient preferences and
values.
The panel identified this as an important knowledge gap, and
additional studies are needed.
DOACs vs LMWH for long-term anticoagulation. SUMMARY OF
THE EVIDENCE. We identified 4 systematic reviews addressing, in part,
this question.307,312,313,332 We considered only studies that
provided results for patients with active cancer at enrollment. From
these reviews, we identified 1 eligible RCT that fulfilled our inclusion
criteria and measured outcomes relevant to this question.396
Assessed outcomes were recurrent VTEs, major bleeding, and
mortality. The EtD framework is available at https://guidelines.ash.-
gradepro.org/profile/kP1qhVfvjlw.
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BENEFITS. In the setting of long-term anticoagulation for secondary
prophylaxis, compared with LMWHs, DOACs may reduce recurrent
VTEs, recurrent PEs, and recurrent DVTs, but the evidence is very
uncertain. The panel judged the effect to be moderate (for recurrent
VTEs beyond 6 months: RR, 0.69; 95% CI, 0.47-1.01; ARR, 34
fewer per 1000; 95% CI, 59 fewer to 1 more per 1000 using a
baseline risk of 11.1%299; for recurrent DVTs beyond 6 months: RR,
0.54; 95% CI, 0.31-0.93; ARR, 51 fewer per 1000; 95% CI, 8-77
fewer per 1000 using a baseline risk of 11.1%299; for recurrent PEs
beyond 6 months: RR, 0.96; 95% CI, 0.57-1.61; ARR, 4 fewer per
1000; 95% CI, 48 fewer to 68 more per 1000 using a baseline risk of
11.1%).299
HARMS AND BURDEN. In the setting of long-term anticoagulation for
secondary prophylaxis, compared with LMWHs, DOACs may
increase the risk of mortality and major bleeding, but the evidence
is very uncertain. The panel judged this effect to be small (for
mortality beyond 6 months: RR, 1.07; 95% CI, 0.92-1.25; ARI, 24
more per 1000; 95% CI, 28 fewer to 87 more per 1000 using a
baseline risk of 34.7%299; for major bleeding beyond 6 months: RR,
1.71; 95%CI, 1.01 to 2.88; ARI, 72 more per 1000; 95%CI, 1-192
more per 1000 using a baseline risk of 10.2%).
CERTAINTY IN THE EVIDENCE OF EFFECTS. The certainty in these estimated
effects was judged as very low because of the risk of bias and
imprecision of the estimates.
OTHER ETD CRITERIA AND CONSIDERATIONS. No study about resource
utilization was identified, and the panel noted that resource use
varies, depending on the risk of recurrent VTEs and other
complications, such as major bleeding, settings, and populations,
which will also vary over time. Only cost-effectiveness data from the
general population were available. Equity might vary depending on
the access to drugs, such as DOACs or LMWHs, which might not
be widely available. The interventions are probably acceptable and
feasible to implement. Although DOACs are administered orally
without routine monitoring and, therefore, are generally feasible,
they are not appropriate for some clinical settings (severe renal
dysfunction defined as creatinine clearance ,30 mL/min, preg-
nancy, drug-drug interactions), and they may not be available in all
clinical practice settings. For some patients, drug interactions could
also be a concern.
CONCLUSIONS AND RESEARCH NEEDS FOR THESE RECOMMENDATIONS. The
conditional recommendation for continuing indefinite anticoagula-
tion using DOACs or LMWH was a result of the overall balance of
efficacy and safety that does not favor the intervention or the
comparison, in the context of low certainty in the evidence and
uncertainty in the relative cost-effectiveness. The choice of
treatment must be based on the specific clinical setting (to minimize
risk), patient preference, and the availability of treatment options,
including cost considerations.
Although there is a critical need for further studies to confirm the
benefits of long-term anticoagulation for secondary prevention for
patients with active cancer, the panel recognizes the challenges in
conducting such studies because of limitations of enrollment.
What others are saying and what is new in
these ASH guidelines?
There are 3 other recent guidelines available on the prevention and
treatment of VTEs in patients with cancer: the 2019 American
Society of Clinical Oncology (ASCO) guidelines,397 the 2019
International Initiation on Thrombosis and Cancer (ITAC) guide-
lines,398 and the 2020 National Comprehensive Cancer Network
guidelines.399 Two major differences between the ASH guidelines
and the others is the consistent use of systematic reviews and EtDs,
which increases transparency and trustworthiness, as well as the
use of marker states to estimate the relative importance of key
outcomes of treatment to patients.
All guidelines recommend assessing the risk of VTE and bleeding in
hospitalized medical and surgical patients with cancer. For patients
with a high risk for thrombosis and a low risk for bleeding, routine
pharmacological thromboprophylaxis is recommended. However,
recommendations around the timing of initiation of pharmacological
thromboprophylaxis among patients undergoing cancer-related
major abdominal surgery differ, which highlights the lack of data in
that setting and the requirements for additional studies. For patients
undergoing major cancer surgery, the ASCO guidelines advise
starting thromboprophylaxis preoperatively. ITAC also suggests
initiation 2 to 12 hours preoperatively, whereas the ASH guidelines
recommend initiating thromboprophylaxis postoperatively, given the
limited advantages to initiating thromboprophylaxis preoperatively,
in addition to the potential bleeding and logistical considerations
associated with neuraxial anesthesia. Similarly, the 3 other clinical
practice guidelines acknowledge the importance of stratifying
ambulatory cancer patients beginning chemotherapy according
to their underlying risk of VTE. The ASH guideline suggests
stratifying patients into groups who are at low, intermediate, or
high risk for VTEs, and it provides recommendations on the use
of pharmacological thromboprophylaxis in these different sub-
groups. The DOACs are also now considered pharmacological
options for ambulatory cancer patients at intermediate to high
risk for VTEs. DOACs (apixaban and rivaroxaban) are considered
safe and effective options for the treatment of cancer-associated
thrombosis. All clinical practice guidelines have assessed and
incorporated new data comparing LMWH with DOACs for this
indication.
The ASCO guidelines divide the treatment course into initial
anticoagulation and long-term ($6 months) anticoagulation.
LMWH, UFH, fondaparinux, or rivaroxaban is suggested for the
initial treatment of VTEs in patients with cancer. For long-term
anticoagulation, LMWH, edoxaban, or rivaroxaban for$6 months is
preferred because of improved efficacy over VKAs. The ITAC
guideline also suggests using LMWH, UFH, DOACs, or fondapar-
inux during the treatment initiation and LMWH or DOACs during
early maintenance treatment (initial 6 months). Given the complexity
of anticoagulation management in cancer patients with VTEs, the
ASH guidelines divided the treatment course into initial treatment
(within the first week), short-term anticoagulation (initial 3-6 months),
and long-term anticoagulation (.6 months). The ASH guidelines
suggest LMWH or DOACs (rivaroxaban or apixaban) for initial
treatment; if a DOAC is not chosen, the ASH guidelines recommend
LMWH over UFH or fondaparinux. For the short-term treatment of
VTEs (3-6 months), DOACs (apixaban, edoxaban, and rivaroxaban)
are suggested over LMWH. VKAs are not recommended; the
same regimen is recommended for long-term anticoagulation
(.6 months). All guidelines recommend caution in using DOACs in
patients with GI cancers because of the higher reported risk of
bleeding complications. Finally, the ASH guidelines consider other
important issues related to the management of cancer-associated
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thrombosis, including splanchnic vein thrombosis, incidental PEs,
and SSPEs.
Limitations of these guidelines
The limitations of these guidelines are inherent in the low or very
low certainty in the evidence that we identified for many of the
questions.
Revision or adaptation of the guidelines
Plans for updating these guidelines
After publication of these guidelines, ASH will maintain them
through surveillance for new evidence, ongoing review by experts,
and regular revisions.
Updating or adapting recommendations locally
Adaptation of these guidelines will be necessary in many circum-
stances. These adaptations should be based on the associated EtD
frameworks.400 The Agency for Healthcare Research and Quality in
the United States provides a guide for implementing effective quality
improvement in this patient population.401
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363. Gómez-Outes A, Lecumberri R, Suárez-Gea ML, Terleira-Fernández AI, Monreal M, Vargas-Castrillón E. Case fatality rates of recurrent thromboembolism
and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous thromboembolism: a systematic review.
J Cardiovasc Pharmacol Ther. 2015;20(5):490-500.
364. Cundiff DK. Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism. Medscape J Med.
2008;10(11):258.
365. Simes J, Becattini C, Agnelli G, et al; INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism). Aspirin
for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation. 2014;130(13):1062-1071.
366. Streiff MB, Segal JB, Tamariz LJ, et al. Duration of vitamin K antagonist therapy for venous thromboembolism: a systematic review of the literature. Am J
Hematol. 2006;81(9):684-691.
367. Sindet-Pedersen C, Pallisgaard JL, Olesen JB, Gislason GH, Arevalo LC. Safety and efficacy of direct oral anticoagulants compared to warfarin for
extended treatment of venous thromboembolism -a systematic review and meta-analysis. Thromb Res. 2015;136(4):732-738.
368. Middeldorp S, Prins MH, Hutten BA. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database
Syst Rev. 2014;(8):CD001367.
369. Marik PE, Cavallazzi R. Extended anticoagulant and aspirin treatment for the secondary prevention of thromboembolic disease: a systematic review and
meta-analysis. PLoS One. 2015;10(11):e0143252.
370. Pinede L, Duhaut P, Cucherat M, Ninet J, Pasquier J, Boissel JP. Comparison of long versus short duration of anticoagulant therapy after a first episode of
venous thromboembolism: a meta-analysis of randomized, controlled trials. J Intern Med. 2000;247(5):553-562.
371. Sobieraj DM, Coleman CI, Pasupuleti V, Deshpande A, Kaw R, Hernandez AV. Comparative efficacy and safety of anticoagulants and aspirin for extended
treatment of venous thromboembolism: A network meta-analysis. Thromb Res. 2015;135(5):888-896.
372. Ost D, Tepper J, Mihara H, Lander O, Heinzer R, Fein A. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA. 2005;
294(6):706-715.
373. Castellucci LA, Le Gal G, Rodger MA, Carrier M. Major bleeding during secondary prevention of venous thromboembolism in patients who have
completed anticoagulation: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):344-348.
374. Bova C, Bianco A, Mascaro V, Nobile CG. Extended anticoagulation and mortality in venous thromboembolism. A meta-analysis of six randomized trials.
Thromb Res. 2016;139:22-28.
375. Cohen AT, Hamilton M, Bird A, et al. Comparison of the non-VKA oral anticoagulants apixaban, dabigatran, and rivaroxaban in the extended treatment and
prevention of venous thromboembolism: systematic review and network meta-analysis [published correction appears in PLoS One. 2016;11(9):
e0163386]. PLoS One. 2016;11(8):e0160064.
376. Castellucci LA, Cameron C, Le Gal G, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of
venous thromboembolism: systematic review and network meta-analysis. BMJ. 2013;347:f5133.















E user on 12 February 2021
377. Sardar P, Chatterjee S, Mukherjee D. Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic
review and meta-analyses of randomized controlled trials. Drugs. 2013;73(11):1171-1182.
378. Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor’s Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban
in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc
Surg. 2014;48(5):565-575.
379. Alotaibi G, Alsaleh K, Wu C, McMurtry MS. Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-
analysis. Int Angiol. 2014;33(4):301-308.
380. Holley AB, King CS, Jackson JL, Moores LK. Different finite durations of anticoagulation and outcomes following idiopathic venous thromboembolism: a
meta-analysis. Thrombosis. 2010;2010:540386.
381. Agnelli G, Buller HR, Cohen A, et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;
368(8):699-708.
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